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Summary 
Antiviral medication is an important option for treatment of influenza virus infections. 
Two classes of anti-influenza drugs are available for prophylaxis and treatment of the 
infections: M2 ion channel inhibitors and neuraminidase inhibitors. However, most of 
the currently circulating influenza A virus strains are resistant to M2 inhibitors, and wide 
spread application of neuraminidase inhibitors is increasing resistance to these drugs. 
Therefore, discovery of new antiviral drugs and more efficient therapeutic approaches 
are urgently needed.  
The hemagglutinin (HA) protein is the major membrane glycoprotein of influenza A 
viruses. It facilitates binding of the virus to host cell receptors and mediates fusion 
between viral and endosomal membranes. Precursor HA0 must be activated by host 
proteases to gain its fusion capacity. The cleavage motif of HA is a major determinant 
of influenza virus pathogenicity. HA of highly pathogenic avian influenza virus (HPAIV) 
of subtypes H5 and H7 contains a multibasic cleavage motif, which is activated by the 
eukaryotic subtilase furin. Furin’s essential role during the HPAIV infection makes it an 
attractive drug target. Novel peptidomimetics imitating the furin recognition motif -R-X-
K/R-R- proved to be efficacious anti-HPAIV inhibitors. They interfered with the 
proteolytic activation of HA and suppressed virus replication in cell cultures. 
Combination of oseltamivir and ribavirin with a furin inhibitor had synergistic antiviral 
effects. Furthermore, it suppressed the development of oseltamivir-resistant variants. 
Therefore, combination treatment is considered as a promising approach for the 
control of HPAIV.  
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Zusammenfassung 
Zur Therapie und Prophylaxe von Influenza beim Menschen Medikamente aus zwei 
Wirkstoffklassen sind zugelassen: die M2-Ionenkanalblocker und Neuraminidase-
Inhibitoren (Oseltamivir). Die M2-Ionenkanalblocker Amantadin und Rimantadin 
hemmen die Freisetzung des viralen Ribonukleokapsids ins Zytoplasma. Sie führen 
aber bei ihrer Anwendung zu resistenten Virusmutanten und werden daher nicht mehr 
zur Prophylaxe und Therapie von Influenzavirusinfektionen empfohlen. Auch nehmen 
Oseltamivir-resistente Influenzaviren weltweit zu. Daher sind neuartige Wirkstoffe und 
neue Strategien zur Bekämpfung von Influenzavirusinfektionen dringend erforderlich.  
Die proteolytische Spaltung des Hämagglutinins (HA), eines Glykoproteins an der 
Oberfläche der Influenzaviren, ist Voraussetzung für deren Infektiosität. Bei den hoch 
pathogenen aviären Influenzaviren (HPAIV) der Subtypen H5 und H7 wird das HA-
Vorläufermolekül (HA0) von der Wirtsprotease Furin am Carboxyterminus des 
basischen Peptidmotivs –Arg-X-Arg/Lys-Arg- in die Untereinheiten HA1 und HA2 
gespalten. In dieser Arbeit wurde die Hemmung von HA-Spaltung und 
Virusvermehrung durch neuartige Protease-Inhibitoren untersucht. Es handelte sich 
dabei um Peptidomimetica, die strukturelle Ähnlichkeit mit den HA-Spaltstelle haben. 
Sowohl die Spaltung des HAs als auch die Ausbereitung von HPAIV in Zellkulturen 
wurde durch den Furininhibitor MI-701 besonders effizient gehemmt. Die Kombination 
von MI-701 mit Oseltamivir und Ribavirin steigerte die antivirale Hemmwirkung enorm. 
Darüber hinaus kam es bei gleichzeitige Gabe von MI-701, Oseltamivir und Ribavirin 
zur eine stark verzögerten Ausbildung von Oseltamivir-resistenten Viren (HPAIV). Den 
Kombination von Furininhibitoren mit konventionellen antiviralen Substanzen bietet 
sich deswegen als besonders wirksame Methode zur Behandlung von HPAIV-
Infektionen an.  
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1. Introduction 
1.1 Influenza 
Influenza is a common infectious disease in human. The infection typically causes a 
transient respiratory illness, in severe cases, however, it may also lead to death. 
Influenza viruses spread worldwide and cause annual epidemics and sporadic 
pandemics. Influenza A viruses have been isolated not only from human, but also from 
many other mammalian species including pigs, whales, horses, seals, bats, but the 
original reservoir of all influenza A viruses are birds (Webster et al., 1992). 
1.1.1 Classification 
Influenza viruses belong to the family Orthomyxoviridae, which is a family of enveloped 
viruses with segmented, negative-stranded RNA genes. There are six different genera 
in this family; Influenza virus A, Influenza virus B, Influenza virus C, Isa virus, Thogoto 
virus and recently discovered Quaranja virus. These viruses are serologically 
differentiated by their internal proteins: the matrix protein and nucleoprotein (Fields, 
2006; Presti et al., 2009). Influenza A viruses are further divided into 18 hemagglutinin, 
H1-H18, and 11 neuraminidase subtypes, N1-N11, based on different antigenicity of 
their HA and NA molecules (Fields, 2006; Tong et al., 2012; Tong et al., 2013). 
Influenza strains are named according to their genus, the host of origin (except for 
humans), the location of isolation, the number of the isolate, the year of isolation and 
the HA and NA subtypes. For example, A/Thailand/1(KAN-1)/2004 (H5N1) describes 
an influenza A virus subtype H5N1, which was isolated from a human in Kanchanaburi, 
a province of Thailand, in 2004 with the strain number 1 (Puthavathana et al., 2005). 
1.1.2 Clinical features and pathogenesis of influenza 
1.1.2.1 Human influenza viruses 
Currently, influenza A virus, subtypes H1N1 and H3N2, and two lineages of influenza 
B virus, B/Vitoria/2/87-like (Victoria lineage) and B/Yamagata/16/88-like (Yamagata 
lineage), are co-circulating among humans (WHO1). Human influenza viruses usually 
affect the human respiratory tract: the nose, trachea, bronchi and lungs, resulting in 
mild upper respiratory diseases and rarely induce severe lower respiratory diseases 
(Fields, 2006). The flu syndrome is typically a sudden onset of high fever, chills, dry 
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cough, sore throat, runny nose, headache, muscle and joint pain, fatigue, and in severe 
cases breathing problems and pneumonia. The incubation period can be as short as 
24 hours to 4 or 5 days (Fields, 2006). Influenza epidemics normally occur during the 
winter and affect people of all ages. However, children under 2 years old, the elderly 
aged more than 65 years, and people of any age with pre-existing medical conditions, 
metabolic diseases or weakened immune systems are at highest risks of developing 
flu-related complications (Rothberg et al., 2008).  
1.1.2.2 Avian influenza viruses 
Influenza A viruses isolated from birds are termed avian influenza viruses. The first 
outbreak of avian influenza was reported in Italy in 1878 by Perroncito (Perroncito et 
al., 1878). It caused high mortality in chickens and was originally termed as fowl plague. 
A filterable virus was first determined to cause this disease (Centanni et al., 1901). 
Influenza A viruses was identified as the causative agent of fowl plague in 1955 
(Schäfer, 1955; Lupiani & Reddy, 2009).  
Avian influenza viruses are categorized as either low pathogenic avian influenza virus 
(LPAIV) or highly pathogenic avian influenza virus (HPAIV) based on their 
pathogenicity in chickens. LPAIV usually cause little to no diseases in wild birds. Its 
infection is limited to the intestinal tract of birds. High concentrations of viruses are 
shed in feces (Alexander, 2007; Webster et al., 1992). HPAIVs are highly pathogenic 
for chickens and cause severe contagious illness and death among infected birds. 
Currently, only some strains of influenza A subtypes H5 or H7 have the potential to 
shift from low pathogenic to highly pathogenic by spontaneous insertion of basic amino 
acids at the HA0 cleavage site (Perdue et al., 1997; Garten & Klenk, 2008). Although 
most avian influenza viruses do not infect humans, human infections with LPAIV or 
HPAIV may sporadically occur after direct contact with infected poultry. Infection of 
LPAIV generally results in mild respiratory diseases, whereas infection of HPAIV can 
cause severe lower respiratory disease and high mortality in humans (Fields, 2006; 
Garten & Klenk, 2008).  
1.1.2.2.1 Avian influenza H7 viruses  
Over the past 60 years outbreaks of LPAIV and HPAIV H7 viruses, including H7N1, 
H7N2, H7N3, H7N4, H7N7 and H7N9 subtypes, occurred throughout the world, 
resulting in mass culling of poultry and domestic birds and devastating economic 
losses (Alexander, 2000; Capua & Alexander, 2004; Belser et al., 2009) (Table S1 in 
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supplementary). Some H7 strains crossed the species barrier and infected humans. 
Human infection with H7 viruses mainly results in conjunctivital symptoms with 
occasional and generally mild respiratory illness (Belser et al., 2009). The first 
documented isolation of HPAIV H7 subtypes from human occurred in 1959 in the 
United States (Delay et al., 1967), while the first direct transmission of H7 subtype from 
infected birds to human occurred in 1996 in England (Kurtz et al., 1996). Since then, 
human infections with H7 subtype have been reported in countries worldwide, including 
Canada, Italy, Mexico, the Netherlands, the United Kingdom, and the United States 
(Table 1.1).  
 
Table 1.1: Human cases of influenza A virus H7 subtype infection since 1996. 
 
*Table is taken from Belser et al., 2009 with modification. 
ARDS: acute respiratory distress syndrome. 
 
The largest outbreak of HPAIV H7N7 subtype in humans occurred in February 2003 in 
the Netherlands. More than 30 million birds and chickens were slaughtered during this 
outbreak, and 86 humans who handled infected poultry were infected, as well as three 
of their family members. The symptoms were generally mild; however, one case was 
severe and the patient died after developing an acute respiratory distress syndrome 
(ARDS) and pneumonia (Fouchier et al., 2004). In 2004 two people in Canada were 
infected with HPAIV H7N3 subtype and developed mild influenza-like illness and 
conjunctivitis (Tweed et al., 2004). In 2013 an outbreak of LPAIV subtype H7N9 
occurred in China. Most patients developed severe pneumonia. By February 2014 a 
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total of 375 human cases of H7N9 infection had been confirmed, including 115 deaths. 
The source of the virus has not been identified and therefore the risk of infection with 
H7N9 is still present (WHO2). 
1.1.2.2.2 Avian influenza H5 viruses  
The first documented outbreak of avian influenza H5 viruses in poultry occurred in 
Scotland in 1959 (Becker et al., 1967). Within the past fifty years, over ten outbreaks 
of H5 viruses have occurred worldwide, including several large outbreaks of HPAIV H5 
viruses that affected huge amounts of domestic poultry (Table S2 in supplementary). 
The outbreak of HPAIV H5N1 in 2003 in Asia, affecting South Korea, Japan, Indonesia, 
Vietnam, Thailand, Laos, Cambodia and China, resulted in high mortality in poultry and 
wild birds. Since 2003, the HPAIV H5N1 viruses extended from Asia to Europe, the 
Middle East and Africa, and caused endemics in Bangladesh, China, Egypt, India, 
Indonesia and Vietnam (Lupiani & Reddy, 2009). 
The first human infection with avian influenza virus H5N1 was reported in Hong Kong 
in 1997. Eighteen people were infected with this virus and six of them died (Shortridge 
et al., 1998). No other additional cases were reported until 2004, when human 
infections with HPAIV H5N1 were reported in Vietnam (Tran et al., 2004). Infection of 
HPAIV H5N1 causes severe pneumonia and multi-organ failure (Abdel-Ghafar et al., 
2008). Since 2003, a total of 650 human infection cases have been confirmed and 386 
people died (Table. 1.2) (WHO3). Until now, the HPAIV H5N1 virus is not able to 
efficiently and sustainably transmit from human-to-human. Most cases of H5N1 
infection in humans are linked to direct contact with infected poultry. However, the 
frequent occurrence of H5N1 infections in wild birds and poultry increases the risk of 
human exposure to H5N1 viruses. Therefore, the HPAIV H5N1 virus is considered to 
have potential to cause a new pandemic. 
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Table 1.2: Confirmed human H5N1 cases from 2003 to 2014.  
 
This table is taken from cumulative number of confirmed human cases for avian influenza A (H5N1) 
reported to WHO, 2003-2014, with modification (WHO4). 
 
1.1.3 Epidemiology 
1.1.3.1 Antigenic drift and antigenic shift 
Influenza A viruses exhibit rapid evolutionary dynamics, consistent with a high average 
mutation rate, ranging from 10-3 to 8 x 10-3 substitutions per site per year during viral 
genome replication (Chen & Holmes, 2006). Influenza viruses can rapidly change in 
two different ways: antigenic drift and antigenic shift. Antigenic drift refers to small 
changes that are caused by point mutations such as amino acids substitution in HA 
and NA or a cluster of mutations in antigenic epitopes. It occurs frequently and may 
result in minor changes in antigenicity that allow the virus to escape host pre-existing 
immunity induced by previous infection or vaccination. Antigenic drift occurs in all 
strains of influenza A and B viruses and much more often in influenza A virus H3 
subtype (Carrat & Flahault, 2007). Antigenic shift is defined as major antigenic change 
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in HA or NA proteins, which produces a new virus subtype. This has only been found 
in influenza A viruses and occurs when different viruses, from either different subtypes 
or different host species co-infect the same host cell and new influenza subtypes are 
produced by genetic reassortment (Fields, 2006) (Fig. 1.5). 
1.1.3.2 History of human influenza pandemics 
In the past hundred years 4 major human influenza pandemics have occurred at 
intervals of 10 to 50 years with varying severity and caused millions of fatalities 
worldwide (Fig.1.1).  
 
 
 
Fig. 1.1: Recorded human influenza pandemics since 1918. Figure is taken from Ahmed et al., 2007 
with modification. 
 
1918 Spanish flu (H1N1): The “Spanish flu” was the most devastating influenza 
pandemic, killing more than 40 million people worldwide. In 1997, the genomic RNA of 
the 1918 virus was recovered from preserved lung tissue from a victim of the 1918 
pandemic, as influenza virus could not be isolated before 1933 (Fields, 2006; 
Taubenberger et al., 1997).  
1957 Asian Flu (H2N2): This pandemic originated in southern China and quickly 
spread to Singapore in February 1957, to Hong Kong in April and reached the US by 
June. It killed approximately 2 million people and mostly affected younger individuals 
aging 5-19 years old. Genetic and biochemical analysis indicated that the 1957 
pandemic virus was the result of genetic reassortment of previously circulating human 
H1N1 virus and avian viruses (Fields, 2006; Kilbourne, 2006).  
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1968 Hong Kong Flu (H3N2): The Hong Kong flu began in Southern Asia and killed at 
least 1 million people around the world. It was caused by an influenza A H3N2 strain, 
which shared the same NA with previously circulating Asian flu H2N2 viruses, but 
contained a different HA. The Hong Kong pandemic was not as severe as the H2N2 
pandemic. It is believed that the pre-existing antibody to the NA (N2) protein in people 
moderated the severity of this pandemic (Field, 2006; Cox & Subbarao, 2000). 
2009 Pandemic swine flu (pandemic 2009 H1N1): The 2009 pandemic swine flu is the 
first global influenza pandemic of the 21th century. The novel H1N1 virus was first 
identified in Mexico and the United States in March and early April 2009. It is a triple-
reassortant swine influenza virus, possessing NA and M genes from Eurasian avian-
like swine virus (H1N1), HA, NP and NS genes from classical swine virus, PB2 and PA 
genes from North American avian virus and the PB1 gene from human H3N2 virus 
(Smith et al., 2009). Shortly after its emergence, the virus spread quickly across the 
world and on 11th June 2009 WHO declared a phase 6 influenza pandemic alert, which 
is the maximum phase of a pandemic alert (WHO5).  
1.1.4 Virus morphology, genome and proteins 
Influenza viruses are pleomorphic, spherical, and sporadically also filamentous. 
Spherical particles are of about 80-120nm in diameter, filamentous particles can reach 
more than 20µm in length (Noda, 2011). The genomes of influenza A and B viruses 
are segmented into 8 single-stranded RNA molecules, while influenza C viruses have 
only 7 RNA segments. 
The segmented genomes of influenza A virus encode for at least 10 major viral proteins, 
polymerase basic 1 (PB1), polymerase basic 2 (PB2), polymerase acid (PA), 
hemagglutinin (HA), nucleoprotein (NP), neuraminidase (NA), matrix protein 1 (M1), 
matrix protein 2 (M2), nonstructural proteins 1 (NS1) and 2 (NS2, also called nuclear 
export protein, NEP) (Fields, 2006) (Fig.1.2). 
Two viral glycoproteins, HA and NA are inserted in the viral lipid membrane, which is 
derived from the host cells. HA is more abundant than NA. The HA protein is a rod-like 
shaped homotrimer, which mediates the binding of viral particles to the cellular 
glycoconjugates with terminal sialic acid (N-acetyneuraminic acid). It is also 
responsible for the fusion between viral and endosomal membranes. The NA protein 
is a mushroom-shaped homotetramer. It removes sialic acid residues from virus and 
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host cell receptors after infection and thereby prevents self-aggregation of progeny 
viruses and facilitates the release of mature virions.  
 
         
 
Fig. 1.2: Structure of influenza A virus. (A) Scheme of influenza A virus. Influenza A virus is an 
enveloped virus containing 8 segmented RNA genomes. Three membrane proteins, hemagglutinin (HA), 
neuraminidase (NA) and matrix protein 2 (M2) are inserted in the viral membrane which is derived from 
host cell membrane. The matrix protein (M1) lies beneath the viral membrane. The viral RNA genome 
segments are associated with nucleoprotein (NP) and three polymerase subunits (PA, PB1 and PB2), 
(B) EM image was kindly provided by Dr. Larissa Kolesnikova, Institute of Virology, Marburg. 
 
The M2 protein, a homotetrameric, type III integral membrane protein, is also 
embedded in the viral lipid envelope. It functions as an ion channel, which allows the 
passage of protons into the interior of virus leading to acidification and dissociation of 
the matrix protein M1 and the release of viral RNP complex into the cytoplasm (Fields, 
2006). The M2 protein is also involved in the virus assembly process at the plasma 
membrane (Lamb et al., 1985). 
The M1 protein lies beneath the lipid membrane. It is the most abundant protein in viral 
particles. It mediates the interaction between the envelope and the viral RNPs. Within 
the interior of the viral particle are the segmented RNA genomes. Each RNA segment 
is coated with NP and a viral polymerase complex and forms rod-shaped, double-
helical RNPs. The RNPs plays an important role in virus transcription and replication.  
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Table 1.3: Functions of influenza viral proteins  
 
 
The NS1 protein is a homodimeric RNA-binding protein that is highly expressed in 
infected cells (Fields, 2006). It exhibits multiple functions during virus infection (Hale 
et al., 2008), including the regulation of mRNA splicing and translation (Chien et al., 
1997), the nuclear export of viral mRNA (Qian et al., 1994), inhibition the host interferon 
(IFN)-mediated antiviral response (García-Sastre et al., 1998) and also interacts with 
several host factors.  
The NS2/NEP protein is derived through splicing of NS1 mRNA. NS2/NEP is localized 
in the cell nucleus and interacts with the M1 proteins, thereby mediating the 
translocation of vRNPs across nuclear pores (O’Neill et al., 1998). 
Since influenza virus RNA replication takes place in the host cell nucleus, it has the 
advantage of using the host splicing mechanism to enhance its genomic coding 
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capacity. In addition to the splicing products, M2, PB1-F2 and NS2/NEP, several novel 
influenza A virus proteins have currently been identified: PB1-N40, encoded by 
segment 2 mRNA (Wise et al., 2009), PA-X, PA-N155, PA-N182, three additional 
products of segment 3 (Jagger et al., 2012; Muramoto et al., 2013) and M42, which is 
generated by segment 7 (Wise et al., 2012). 
1.1.5 Virus life cycle 
Influenza virus infection is initiated by HA protein binding to sialic acid (SA)-containing 
host cell receptors. After binding, the virus is internalized by receptor-mediated 
endocytosis. The low pH in the endosomes induces conformational changes of cleaved 
HA, which exposes the HA2 fusion peptide, allowing the fusion between viral and 
endosomal membranes and the uncoating of viral RNPs, resulting in the release of 
viral RNPs into the cytoplasma. By using nuclear transport signals of NP, the viral 
RNPs are transported via the classical importin-α/β1 pathway from the cytoplasma into 
the nucleus, where the viral transcription and replication take place (Fields, 2006; 
Gabriel et al., 2011). Once the vRNPs enter the nucleus, the incoming negative-
stranded RNAs are transcribed to messenger RNAs (mRNAs). This transcription 
process is catalyzed by the influenza viral polymerase complex, which uses a short-
capped primer, derived from the 5'-capped RNA fragments from host pre-mRNAs by a 
unique ‘cap-snatching’ mechanism. This primer aligns on the templates and provides 
a starting point for positive stranded RNA synthesis (Fig. 1.3).  
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Fig. 1.3: Influenza virus life cycle. With the help of HA influenza virus binds to sialic acid-containing 
host receptors. After receptor-mediated endocytosis and HA-mediated fusion between viral and 
endosomal membrane, viral ribonucleoprotein (vRNP) complexes are released into the cytoplasm and 
then transported into the nucleus, where replication and transcription take place. Translation of 
messenger RNAs (mRNAs) occurs in the cytoplasm. Newly synthesized vRNPs are exported out of the 
nucleus with the help of the M1 and NS2 proteins. The assembly and budding of progeny virions occurs 
at the plasma membrane. 
 
Three membrane proteins, HA, NA and M2 proteins are synthesized in the 
endoplasmic reticulum (ER) and then transported from the ER through cis-, trans-Golgi 
network (TGN) to the apical plasma membrane in polarized epithelial cells. Finally virus 
particles are assembled at the plasma membrane where raft lipids are enriched (Nayak 
et al., 2009) During transport to the cell surface, these transmembrane proteins are 
folded, oligomerized (HA: trimer, NA and M2: tetramer), N-glycosylated (HA and NA), 
palmitoylated (HA and M2) and phosphorylated (M2).  
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The NP, M1, NS1 and NS2/NEP proteins are transported from the cytoplasma back 
into the nucleus and bind to newly formed vRNAs. Replication of virial genomes occurs 
in a two-step process in the nucleus. The full-length complementary RNAs (cRNAs) of 
positive polarity are first generated and in turn are used as templates for synthesis of 
additional negative-sense vRNAs. With the help of M1, NEP and NP proteins newly 
synthesized vRNAs are exported out of the nucleus via the cellular chromosomal 
maintenance 1 (Crm1) also known as Exportin 1-mediated nuclear export pathway 
(Elton et al., 2001; Chen & Krug, 2000) and are transported to the assembly sites. The 
assembly and budding of progeny virions occur at the plasma membrane.  
1.2 Hemagglutinin 
The HA protein is the major glycoprotein of influenza virus. HA is an important 
determination factor of host range, cell tropism and infectivity of influenza virus (Klenk 
et al., 1975). It is responsible for viral attachment to the sialic acid (SA) containing host 
receptors. Human and classical H1N1 swine influenza viruses bind preferentially to 
2,6-linked SA, whereas most avian and equine viruses exhibit a strong binding affinity 
for 2,3-linked SA (see 1.2.2). Cleavage of HA is a prerequisite for mediating fusion 
between viral and endosomal membrane (see 1.2.3). In addition, the HA protein also 
plays an important role in host immune responses by harboring the major antigenic 
sites responsible for the generation of neutralizing antibodies.  
1.2.1 The structure of the hemagglutinin 
The HA protein is a type I glycoprotein with an N-terminal signal peptide, a large 
ectodomain, a transmembrane domain and a short C-terminal cytoplasmic tail. Each 
HA monomer consists of a globular head unit HA1 (blue), which contains a SA binding 
site, and a stalk unit HA2 (red), which is responsible for the pH-triggered membrane 
fusion between viral and endosomal membranes (Fields, 2006; Klenk et al., 1975; 
Skehel & Wiley, 2002; Harrison, 2008) (Fig. 1.4 and Fig. 1.6A). 
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Fig. 1.4: Crystal structure of the hemagglutinin (HA). (A) Non-cleaved trimeric precursor HA0. (B) 
Cleaved HA trimer. (C) HA2 subunits after conformational changes at low pH. HA1 subunits are in blue, 
HA2 are in red. The cleavage loop and fusion peptide (yellow) are indicated by arrows. Figures were 
modified from Skehel & Wiley, 2002 and Galloway et al., 2013. 
 
1.2.2 Receptor binding specificity of hemagglutinin 
To initiate the infection in host cells the HA protein must bind to the SA on the host cell 
surface. SA is a diverse family of monosaccharides with a 9-carbon backbone. It is 
widely distributed on many cell types and is usually found as the terminal sugar of 
glycoconjugates. The carbon-2 of SA can bind in trans to the carbon-3 or carbon-6 of 
galactose, forming α-2,3-linked SA or α-2,6-linked SA linkages. Human and classical 
H1N1 swine influenza viruses bind preferentially to α-2,6-linked SA, whereas most 
avian and equine viruses exhibit a strong binding affinity for α-2,3-linked SA. The α-
2,6-linked SA are dominant in non-ciliated cells of the human upper respiratory tract 
such as nasopharynx and trachea. The 2,3-linked SA are more commonly located in 
epithelial cells in the gastrointestinal tract of birds and on the ciliated cells and type II 
pneumocytes in the human respiratory tract (Matrosovich et al., 2004; Kumlin et al., 
2008; Ibricevic et al., 2006; Wilks et al., 2012). The epithelial cells in pig trachea contain 
both α-2,3-linked SA and α-2,6-linked SA, which makes pigs susceptible to infection of 
both human and avian influenza viruses and thus act as ‘mixing vessel’ for influenza 
viruses (Scholtissek, 1990) (Fig. 1.5).  
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Fig. 1.5: The role of swine for influenza virus genetic reassortment. Since the trachea of swine 
contains both α-2,3-linked and α-2,6-linked SA, swine is considered to be an appropriate intermediate 
host for generation of novel influenza virus strains by genetic reassortment. Image was taken from 
Stevens et al., 2006 with modification.  
 
1.2.3 Proteolytic activation of precursor hemagglutinin 
Proteolytic cleavage of precursor HA0 into disulfide-linked subunits HA1 and HA2 is 
essential for infectivity of influenza viruses. The cleavage occurs at the C-terminus of 
a conserved arginine residue connecting HA1 and HA2 (Klenk et al., 1975; Lazarowitz 
& Choppin, 1975) (Fig.1.6).  
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Fig. 1.6: Cleavage of hemagglutinin of influenza A viruses. The hemagglutinin precursor (HA0) must 
be cleaved by the host proteases to initiate the infection in the host. (A) Schematic images of the HA0 
precursor and its cleaved form consisting of the disulphide-linked subunits HA1 and HA2. The HA1 
subunit is shown in blue and the HA2 subunit in purple, the fusion peptide (FP) in orange and 
transmembrane domain (TM) in green. (B) HA-activating host cell proteases and their cleavage 
specificity. Table is taken from Böttcher-Friebertshäuser et al., 2013 with modifications. 1Details about 
furin see 1.3.1. 
 
1.2.3.1 Monobasic cleavage site 
Most influenza viruses, including LPAIV and mammalian influenza viruses contain a 
single arginine (R) or in rare cases a lysine (K) at the cleavage site (Garten & Klenk, 
2008). Previously, cleavage of HA with monobasic cleavage site has been thought to 
occur extracellularly when viruses are released from the infected cells. Trypsin (Klenk 
et al., 1975) or trypsin-like proteases such as plasmin (Lazarowitz & Choppin, 1975), 
the factor Xa-like protease (Gotoh et al., 1990), mini-plasmin (Murakami et al., 2001), 
tryptase Clara (Kido et al., 1992) and tryptase TP30 (Sato et al., 2003) have been 
identified for HA0 activation in vitro. However, a study by Boycott et al. indicated that 
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an endosomal protease might be responsible for the proteolytic activation of influenza 
A H1N1 in MDBK cells (Boycott et al., 1994) and the study by Zhirnov et al. showed 
the intracellular activation of influenza viruses in human intestinal Caco-2 cells (Zhirnov 
et al., 2003). In 2006, two serine proteases: transmembrane serine protease 2 
(TMPRSS2) and HAT (human airway trypsin-like protease) in human airway epithelium 
(Böttcher et al., 2006; Garten & Klenk, 2008) were identified for cleavage of HA with a 
monobasic cleavage motif. Cleavage of newly synthesized HA0 by TMPRSS2 occurs 
intracellularly during the transport to the plasma membrane, whereas HAT activates 
HA0 of incoming viruses during attachment and entry into the cell. It also activates the 
progeny viruses during assembly and budding at the plasma membrane (Böttcher-
Friebertshäuser et al., 2010).  
1.2.3.2 Multibasic cleavage site 
In contrast to LPAIV, the HA protein of HPAIV contains a multibasic amino acids motif 
at the cleavage site. HA of most HPAIV contains the consensus sequences R-X-K/R-
R (R= arginine, L=lysine, X = any amino acid) at the cleavage site (Fig. 1.6). This 
cleavage motif is recognized by subtilisin-like endoproteases, furin and PC5/6, which 
are ubiquitously expressed in human tissues (see 1.3) (Stieneke-Gröber et al., 1992; 
Horimoto et al., 1994, Garten & Klenk, 2008). However, there are exceptions. LPAIV 
influenza virus subtype H9N2 isolated in America, Europe, and Africa contains 
monobasic cleavage site, whereas many isolates from Asia and the Middle East 
possess the multibasic cleavage sites R-S-S-R or R-S-R-R, which are proteolytically 
activated by human protease TMPRSS2, HAT and matriptase. Sequences analysis 
showed that these multibasic motifs were formed by amino acids substitution rather 
than by insertion and therefore are not accessible to furin (Baron et al., 2013). Recently, 
the serine protease TMPRSS13 and its splicing product MSPL were shown to cleave 
HA with the multibasic cleavage site -R/K-K-K-R- in the absence of calcium, whereas 
cleavage by furin is strictly calcium-dependent (Okumura et al., 2010).   
1.3 Proprotein convertases 
Proprotein convertases (PCs) are calcium-dependent eukaryotic subtilisin-like 
endoproteases. They are responsible for activating many biologically inactive 
precursor proteins by limited endoproteolysis. There are nine identified members in the 
PCs family, PC1/3, PC2, PC4, PC5/6, PC7, furin (Fuller et al., 1989; Thomas, 2002; 
Seidah & Prat, 2012), paired basic amino acid cleaving enzyme 4 (PACE4) (Kiefer et 
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al., 1991), subtilisin kexin isozyme-1 (SKI-1)/site-1 protease (S1P) (Espenshade et al., 
1999), and proprotein convertase subtilisin/kexin type 9 (PCSK9) (Seidah et al., 2002). 
They commonly contain a prodomain, a conserved catalytic domain, a P domain and 
a variable C-terminal domain. In particular, a catalytic triad, consisting of serine, 
histidine and aspartic acid, is present at corresponding positions in the catalytic domain 
of all members (Nakayama, 1997; Chrétien et al., 2008). The first seven members, 
PC1/3, PC2, PC4, PC5/6, PC7, furin, PACE4, are structurally closer to kexin. They 
cleave precursors at specific single or paired basic amino acids within the motif (K/R)-
Xn-(K/R)↓, where the arrow indicates cleavage site, Xn corresponds to a 0-, 2-, 4- or 6-
amino-acid spacer, and position 1 of the cleavage site is preferred to be an arginine. 
The other two members SKI-1 and PCSK9 cleave the motifs at non-basic residues. 
SKI-1 is a pyrolysin-like serine protease that cleaves precursors within the motif R-X-
(L/V/I)-X↓, where X can be any amino acid except for cysteine and proline. PCSK9 is 
a protease K-like protease that cleaves at VFAQ152↓ (Seidah & Chrétien, 1999; Seidah 
& Prat, 2012). 
1.3.1 Furin 
The prototypic eukaryotic subtilase furin is encoded by gene fur (fes upstream region), 
which is in the upstream region of the fes oncogene (Roebroek et al., 1986). Furin is a 
calcium-dependent, human prohormone-processing endoprotease, which shares 50% 
homology with the catalytic domain of the yeast prohormone convertase Kex2 (Fuller 
et al., 1989). 
Furin is a type I transmembrane protein and exists in all tissues and cells that have 
been examined thus far (Seidah et al., 1994). It is mainly localized in the TGN in a 
steady state. It also can be transported through the constitutive secretory pathway to 
the plasma membrane, where it can be shed or recycled back to the TGN (Schäfer et 
al., 1995; Thomas, 2002). Furin is first synthesized as a pro-furin molecule and 
translocated across the membrane due to its signal peptide into the endoplasmatic 
reticulum (ER) lumen (Fig.1.7). After the loss of the signal peptide in the ER, furin 
undergoes a pH-dependent conformational change, resulting in a rapid autocatalytic 
cleavage after R107 of its N-terminal prodomain. This step is a prerequisite for furin to 
leave the ER and enter vesicles of the exocytic pathway (Leduc et al., 1992; Creemers 
et al., 1995). It must be noted that after its autocatalytic cleavage, the prodomain 
remains associated with the mature furin and acts as a chaperone inhibitor, which 
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retains furin in an inactive state. After translocation into a more acidic environment, the 
TGN, furin undertakes a slower internal secondary autocatalytic cleavage between 
R75 and S76 in the middle of its prodomain, which is not the consensus cleavage site 
of furin (VTKR↓SLSP79). And this cleavage results in the release of its prodomain and 
generates an enzymatic active form of furin, which is membrane anchored (Nakayama, 
1997; Thomas, 2002).   
 
 
 
Fig. 1.7: Scheme of the furin structure. Various domains are presented in different colored bars and 
N-glycosylation sites are indicated by Y. The catalytic triad, aspartic acid (D153), histidine (H194), and 
serine (S368) are labeled by bold D, H and S, respectively. The asparagine (N295), which is the part of 
the oxyanion, is labelled by N. It is conserved in all members of the PCs family, except for the PC2, 
where it is replaced by aspartic acid. The primary autocatalytic motif RTKR and secondary autocatalytic 
motif RGVTKR are highlighted. The arrows indicate the cleavage sites. Figure is modified from Seidah 
& Prat, 2012.  
 
Furin recognizes substrate with a consensus sequence Arg-X-Arg/Lys-Arg↓ (R-X-R/K-
R, X is any amino acid) and efficiently cleaves at the C-terminal arginine residue of this 
motif. Furin has a broad substrate spectrum and cleaves various important cellular 
protein precursors, such as β-nerve growth factor (β-NGF) (Bresnahan et al., 1990) 
and insulin-like growth factor I (IGF-I) (Duguay et al., 1997). It is also responsible for 
proteolytic activation of glycoproteins or fusion proteins of enveloped viruses and 
bacterial toxins (Fig. 1.8 and Table 5.2). Moreover, furin is expressed in many human 
cancer cells, such as non-small cell lung carcinomas, head and neck squamous-cell 
carcinomas and glioblastomas (Thomas, 2002; Seidah & Prat, 2012). 
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Fig. 1.8: Sites of substrates activation by furin. Precursors of β-nerve growth factor (β-NGF), bone 
morphogenetic protein-4 (BMP-4), the insulin-like growth factor 1 (IGF-1), glycoproteins of highly 
pathogenic avian influenza virus (HPAIV), filoviruses, including Ebola virus (EBOV) and Marburg virus 
(MBGV), membrane protein of flaviviruses, including Dengue virus (DENV) and West Nile virus (WNV) 
and fusion protein of paramyxoviruses, including measle virus (MV), Newcasle disease virus (NDV) and 
repiratory syncytial virus (RSV) are all cleaved in the TGN/biosynthetic pathway. Substrates such as 
Anthrax toxin protective antigen (PA), proaerolysin and Clostridium α-toxin are cleaved by furin at the 
cell surface. In mildly acidic early endosomes, furin cleaves substrates, such as Diphtheria toxin, Shiga 
toxin and Pseudomonas exotoxin A. Figure is taken from Gary Thomas, 2000 and Kornelia Hardes, 
Institute of Pharmaceutical Chemistry, Philipps University Marburg, and modified. 
 
1.4 Prevention and treatment of influenza 
1.4.1 Vaccination 
Vaccination is one of the most effective ways to control seasonal epidemics and 
pandemics of influenza. Since the first influenza vaccines became available in the late 
1940s, many efforts have been made to develop safer and more efficacious influenza 
vaccines. Influenza continuously undergoes antigenic drift and shift in HA and NA 
antigens (see 1.1.3.1), once antigenically novel strains appear, vaccines containing 
formerly prevalent strains cannot provide protection against the novel strains. 
Therefore, the composition of the influenza vaccine must be changed every year based 
on recommendations made by the WHO. 
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There are two basic types of influenza vaccines available. One is the inactivated 
influenza vaccine that was first developed in 1940s and is administered via 
intramuscular injection. It is composed of either whole virus or viral fractions, of which 
the virions are disrupted or split with detergents and then the soluble viral envelope 
proteins are purified. Inactivated vaccine is recommended for children over 6 months 
of age and people with chronic medical conditions as well as pregnant women (CDC1).  
The live attenuated influenza vaccine was approved for use in USA in 2003. It is 
administered via nasal spray. In comparison with the inactivated vaccine, the live 
attenuated vaccine is easier to administer and more effective in young children 
(Ambrose et al., 2008). However, attenuated viruses are still living viruses that are able 
to replicate in vivo. Thus, the live attenuated vaccine may cause mild symptoms such 
as rhinorrhea, nasal congestion, fever, or sore throat. Therefore, it is recommended 
only for people aged 2-49 years, but is not recommended for pregnant women, for 
people who have a weakened immune system, or for people with certain chronic 
diseases (CDC1).  
Both inactivated and live attenuated vaccines are produced from embryonated egg or 
cell cultures, containing three strains of influenza viruses: influenza A (H3N2) virus, 
influenza A (H1N1) virus and one influenza B viruses. For the 2013-2014 flu season 
quadrivalent vaccine, containing two influenza A strains and two influenza B strains is 
available and is given as a nasal spray (CDC1).  
Although vaccine is the primary method for influenza prophylaxis, it has several 
disadvantages. Vaccination cannot provide complete protection, as the efficacy of the 
influenza vaccine is related to the age immune competence of the individual receiving 
it and also depends on the match of antigenicity between the vaccine and circulating 
strains. Importantly, it cannot be timely produced to protect people from infection of a 
new pandemic influenza, because current technology requires at least six months to 
develop sufficient amounts of vaccine to meet the worldwide need (Tosh et al., 2010). 
1.4.2 Approved antiviral agents 
Anti-influenza drugs play an indispensible role for non-vaccinated people and for 
certain high-risk populations who are not recommended for vaccination, including the 
very young or the very old, immunocompromised individuals and people with cardiac 
or pulmonary disease. Currently, two classes of anti-influenza drugs are available: 
adamantane derivatives and neuraminidase inhibitors, which target the functional 
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domains of viral proteins and thus provide an inhibitory effect against different strains 
of influenza A viruses. 
1.4.2.1 Adamantane derivatives 
The adamantane derivatives, amantadine (1-adamantanamine hydrochloride) and 
rimantadine (alpha-methyl-1-adamantane-methylaminehydrochloride) have been long 
used for influenza A virus infection treatment (Fig. 1.9). Amantadine was first approved 
for treatment of Asian influenza virus (H2N2) infection in 1966, and in 1976 was 
approved for treatment of influenza A virus infection (De Clercq, 2006). Admantanes 
have antiviral properties against all subtypes of influenza A virus, but not influenza B 
or C virus, because neither possesses M2 proteins. They inhibit virus replication by 
blocking the flow of protons from the acidified endosome into the interior of the virus 
through the M2 ion channel, and thus prevent dissociation of RNPs from M1 proteins 
(uncoating). However, the worldwide rapid emergence of fullly pathogenic and 
transmissible adamantane-resistant viruses has discouraged the use of amantadine 
and its analogs. Up to approximately 30% patients may shed resistant viruses when 
treated with amantadine or rimantadine (Shiraishi et al., 2003). And the work of Suzuki 
et al. showed that a sensitive virus became resistant when passaged more than three 
times in the present of amantadine (Suzuki et al., 2003). Therefore, since 2010 only 
neuraminidase inhibitors are recommended by WHO for treatment of influenza A and 
B virus infection.  
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Fig. 1.9: M2 protein inhibitors. (A) A ribbon representation of the proposed transmembrane domain of 
M2 protein. The rimantadine is colored in red. (B) Surface representation of the rimantadine-binding 
pocket in M2 protein. (C) amantadine and (B) rimantadine are two M2 protein inhibitors, which can block 
the proton channel protein M2. Figure A and B are taken from Schnell & Chou, 2008. Figure C and D 
are taken from De Clercq, 2006. 
 
1.4.2.2 Neuraminidase inhibitors  
Neuraminidase inhibitors are structurally similar to sialic acid. They block the 
neuraminidase activity by competitively binding to the enzymatic active site and 
thereby prevent the release of progeny virions and the further spread of virus 
throughout the upper respiratory tract. Currently, two neuraminidase inhibitors, 
oseltamivir (Tamiflu; ethyl(3R,4R,5S)-4-acetamido-5-amino-3-(1-ethylpropoxy)-1-
cyclohexene-1-carboxylate) and zanamivir (Relenza; 4-guanidino-Neu5Ac2en), have 
been licensed for therapeutic and prophylactic treatment against both influenza A and 
influenza B viruses since 1999 (Fig. 1.10). Oseltamivir is a prodrug, which can be 
administered orally and it is rapidly converted into the active form, oseltamivir 
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carboxylate, by hepatic esterases. Zanamivir is administered by oral inhalation as a 
dry powder (De Clarcq, 2006).  
 
 
Fig. 1.10: Neuraminidase inhibitors. (A) The neuraminidase of group N1 is shown in surface 
representation. Oseltamivir is shown in sticks. Figure A is taken from Russell et al., 2006. Figure B and 
C are taken from De Clercq, 2006. 
 
Neuraminidase inhibitor-resistant viruses have been isolated in neuraminidase 
inhibitor treated patients and through serial passage in the presence of a 
neuraminidase inhibitor in in vitro studies (McKimm-Breschkin, 2000). Oseltamivir-
resistant viruses were detected at a very low frequency in comparison with 
amantadine-resistant viruses. However, since 2007 they have spread worldwide. 
Almost all the tested A/Brisbane/59/2007-like H1N1 influenza strains that circulated 
worldwide in the influenza season 2008-2009 contained the H275Y NA mutation that 
conferred the resistance to oseltamivir. And 1% tested pandemic 2009 H1N1 viruses 
were resistant to oseltamivir (CDC2). 
1.4.3 Other antiviral agents 
Ribavirin has long been known as a broad-spectum antiviral agent. Aerosolized 
ribavirin has been approved for treatment of RSV infection. Oral ribavirin is also used 
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in combination with peginterferon-α for treatment of chronic hepatitis C virus (HCV) 
infection. The intravenous form of ribavirin has been registered for the treatment of 
haemorrhagic fever with renal syndrome (HFRS). The main target of ribavirin is inosine 
5’-monophosphate (IMP) dehydrogenase, a cellular enzyme which is responsible for 
the conversion of IMP to xanthosine 5’-monophosphate, a key enzyme involved in the 
biosynthesis of guanosine triphosphate (GTP) and viral RNA synthesis (Fig. S1 in 
supplementary) (De Clercq, 2006). A triple combination of amantadine, oseltamivir and 
ribavirin has been reported to have synergistic activity against influenza A viruses in 
vitro and in vivo, including against amantadine- and oseltamivir-resistant viruses 
(Nguyen et al., 2009; 2010). 
Global circulation of drug-resistant influenza variants is the major challenge of present 
antiviral therapeutics. Based on the pre-existing antiviral drugs, new antiviral targets 
and strategies need to be exploited for prevention and control of influenza. Several 
new anti-influenza agents have just entered or are expected to enter clinical 
development. Some target the virus, including novel neuraminidase inhibitors, 
laninamivir (Ikematsu & Kawai, 2011) and peramivir (Shetty & Peek, 2012) as well as 
RNA polymerase inhibitor (Favipiravir, T-705) (Furuta et al., 2002). Others target host 
cellular mechanisms, such as the sialidase fusion protein DAS181 (Malakhov et al., 
2006; Moss et al., 2012), which can remove the influenza virus receptor, sialic acids 
from the airway epithelium. Moreover, furin inhibitor is also considered to be a 
promising antiviral agent (Watanabe et al., 1995; Hallenberger et al., 1992; Jean et al., 
2000; Seidah & Prat, 2012; Becker et al., 2010, 2012) (Fig.1.12).  
1.4.3.1 Proprotein convertase inhibitors 
1.4.3.1.1 Furin inhibitors  
The first furin inhibitors based on peptidyl chloromethyl ketones were reported in 1989 
(Garten et al., 1989). These inhibitors, such as dec-RVKR-cmk (Stieneke-Gröber et al., 
1992; Garten et al., 1994) possess a peptidyl segment and a reactive head. The 
peptidyl part is responsible for targeting the enzyme, and the reactive group irreversibly 
labels the enzyme by forming a covalent bond. And in 1992 it was the first time 
suggested as an antiviral therapeutic agent (Hallenberger et al., 1992). Since then, 
many efforts have been made to develop more efficient and potent furin inhibitors. 
Several peptide inhibitors were developed either from the furin recognition sequence 
(Angliker, 1996) or from the furin prodomain (Basak & Lazure, 2003). Another potent 
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furin inhibitor is a polyarginine compound, nona-D-arginine. It inhibits furin with a Ki 
value of 1.3nM (Cameron et al., 2000; Kacprzak et al., 2004). However, its toxicity and 
poor ability to cross the cell membrane may cause big problems for its therapeutic use 
in vivo (Cameron et al., 2000). Recently, several highly potent substrate analogues, 
peptidomimetic furin inhibitors with the Ki values in nanomolar range were synthesized. 
They contain a furin recognition motif and a C-terminal 4-amidinobenzylamide 
mimicking a decarboxylated arginine (Fig. 1.11) (Becker et al., 2010, 2012). These 
inhibitors were examined in vitro and some showed promising inhibitiory efficacies 
against the infection of HPAIV subtype H7N1. Another peptide based furin inhibitor, 
AC-[azaβ3R]ARRRKK[azaβ3R]T-NH2 with the Ki value of 33nM showed potent 
inhibitory activity against the activation of HA of HPAIV and Shiga toxin (Gagnon et al., 
2014). In addition to these peptide based inhibitors, several other nonpeptide inhibitors 
were designed. The first reported nonpeptic compounds are neoandrographolide, a 
diterpene lactone extracted from the medicinally active plant Andrographis paniculata, 
and its succinoyl ester derivatives (Basak et al., 1999). However, to date most 
nonpeptide furin inhibitors exhibit only moderate activity against furin in the micromolar 
to milimolar range. An exception is a series of small molecules. They are the 
guanidinylated aryl 2,5-dideoxystreptamine derivatives (GADDs), which were derived 
from 2,5-dideoxystreptamine. One of these derivatives inhibits furin with a Ki value of 
6nM (Jiao et al., 2006). Some macromolecular compounds also show excellent 
potency against furin, which include naturally occurring human serine protease 
inhibitor 8 (PI8 or Serpin B8) (Dahlen et al., 1998) and genetically modified variants of 
α1-antitrypsin (α1-PDX) (Jean et al., 1999), turkey ovomucoid third domain (Bontemps 
et al., 2007; Lu et al., 1993) and eglin C (Bontemps et al., 2007; Liu et al., 2004) (Table 
5.1). 
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Fig. 1.11: Structure of furin inhibitor MI-701. MI-701 (4-guanidinomethyl-phenylacetyl-Arg-Val-Arg-4-
amidinobenzylamide, 4-Guame-Phac-RVR-Amba) is a substrate analogue inhibitor, consisting of 
residues P1, P2, P3, P4 and P5, which bind in the complementary furin subsites (S1 to S5). Figure is 
taken from the PhD thesis of Kornelia Hardes, Institute of Pharmaceutical Chemistry, Philipps University 
Marburg, with modification. 
 
1.4.4 Combination therapy 
Combination therapies for treatment with human immunodeficiency virus (HIV), chronic 
hepatitis C virus (HCV), influenza virus and Mycobacterium tuberculosis infections 
have shown greater therapeutic efficacy than monotherapy (Langebeek et al., 2014; 
Maruyama et al., 2013; Govorkova & Webster, 2010; Mitchison, 2012). Benefits of 
combination therapy over monotherapy include the possibility of reducing emergence 
of drug-resistance and enhanced inhibitiory efficacy with low concentration of each 
drug, which is thereby dose-sparing and reduces dose-related drug toxicity and side 
effects (Govorkova & Webster, 2010; Hayden, 2013).  
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1.5 Aim of the study 
The aim of this study is to evaluate the inhibitory efficacy of furin inhibitors for the 
treatment of highly pathogenic influenza virus (HPAIV) infection. The most efficacious 
furin inhibitor was thereafter combined with one or two antivirial drugs to achieve 
enhanced therapeutic effects against HPAIV infection.  
A series of peptidomimetic furin inhibitors were screened for their cytotoxicity at 
different concentrations. Compounds that were toxic to the cells at the given 
concentrations were not included in this study. The inhibitory effects of furin inhibitors 
on proteolytic activation of HA, on virus spread from infected cells to their neighboring 
cells, and on muliticycle replication were examined. Moreover, the most efficacious 
furin inhibitor was combined with oseltamivir and ribavirin for treatment of infection 
caused by HPAIVs A/chicken/fowl plaque virus/Rostock/1934 (H7N1) and 
A/Thailand/1(KAN-1)/2004 (H5N1). The effect of the furin inhibitor on the development 
of oseltamivir-resistance has also been analyzed.  
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Fig. 1.12: Antiviral agents target different steps during influenza virus replication. Inhibitors in red boxese target viral protein. Inhibitors in green boxes 
target host factors.   
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2. Materials 
2.1 Chemicals 
Acetic acid           Riedel-de-Haën,Seelze 
Acrylamide Rotiphorese Gel 30          Roth, Karlsruhe 
ε-Aminocapronic acid              Merck Eurolab, Darmstadt 
A m m o n i u m  p e r o x o d i s u l p h a t e  ( A P S )             Biorad, Richmond (USA) 
Agarose, Ultrapure             Invitrogen, Darmstadt 
Avicel            FMC BioPolymer 
Bovine serumalbumin (BSA)                Serva, Heidelberg 
Bromophenol blue        Serva, Heidelberg 
Dimethyl sulfoxide (DMSO)              Merck Eurolab, Darmstadt 
Disodium hydrogen phosphate (Na2HPO4)           Merck Eurolab, Darmstadt 
dNTP mix           Stratagene, Heidelberg 
Ethanol                   Riedel-de-Haën, Seelze 
Ethidium bromide        Roche, Mannheim 
Ethylenediaminetetra acetic acid (EDTA)           Merck Eurolab, Darmstadt 
Fetal calf serum (FCS)                   Gibco, Karlsruhe 
Formaldehyde              BDH, England 
L-Glutamine 200mM (100x)                  Gibco, Karlsruhe 
Glycerin             Roth, Karlsruhe 
Glycine             Roth, Karlsruhe 
HEPES buffer (1M)                    Gibco, Karlsruhe 
Horse serum        Sigma-Aldrich, Steinheim 
Hydrochloric acid (HCl)              Merck Eurolab, Darmstadt 
Isopropanol                 Merck Eurolab, Darmstadt 
Magnesium chloride (MgCl2 x 6 H2O)            Merck Eurolab, Darmstadt 
β-Mercaptoethanol                Sigma-Aldrich, Steinheim 
Methanol (MeOH)                  Riedel-de-Haën, Seelze 
4-Methyumbelliferone sodium salt (4-MUSS)   Sigma-Aldrich, Steinheim 
MUNANA = 2’-(4-Methylumbelliferyl)-α-D-N-acetylneuraminic acid   
                  Sigma-Aldrich, Steinheim 
Milk powder            Töpfer, Dietmannsried 
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Monopotassium dihydrogen phosphate (KH2PO4)          Merck Eurolab, Darmstadt 
MTT = (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide)        
                  Sigma-Aldrich, Steinheim 
Neutral red                Merck Eurolab, Darmstadt 
Oseltamivir                   F. Hoffmann-La Roche, Nutley, USA 
Paraformaldehyde (PFA)                                          Sigma-Aldrich, Steinheim 
Penicillin/Streptomycin 5000 IU/ml                 Gibco, Karlsruhe 
Potassium chloride (KCl)              Merck Eurolab, Darmstadt 
β-Propiolactone            Sigma-Aldrich, Deisenhofen 
Ribavirin        Sigma-Aldrich, Steinheim 
Seakem LE agarose           Rockland, Maine USA 
Sodium acetate               Merck Eurolab, Darmstadt 
Sodium carbonate (Na2CO3)             Merck Eurolab, Darmstadt 
Sodium chloride (NaCl)              Merck Eurolab, Darmstadt 
Sodium dodecyl sulphate (SDS)             Merck Eurolab, Darmstadt 
Sodium hydroxide(NaOH)              Merck Eurolab, Darmstadt 
Sucrose                M e r c k  E u r o l a b ,  D a r m s t a d t  
N, N, N´, N´ -Tetramethylethylenediamine (TEMED)  Biorad, Richmond (USA) 
Tris(hydroxymethyl)aminomethane (Tris)                                     Roth, Karlsruhe 
Triton X-100           Serva, Heidelberg 
True Blue peroxidase substrate             KPL Protein reasearch Products, 
          Gaithersburg, USA 
Tween-20          Serva, Heidelberg 
2.2 Consumed materials  
Cell culture microplates (6-, 24- und 96-well)     Greiner,Nürtingen 
Cell scraper                  Greiner, Nürtingen 
Microreaction tubes, 1.5ml and 2ml           Eppendorf, Hamburg 
Microreaction tubes (1.5ml, 2ml)            Eppendorf, Hamburg 
Microreaction tubes 1.5ml for ultracentrifuge         Beckman, USA 
Nitrocellulose transfermembrane        Whatman, New Jersey (USA) 
Parafilm        Pechiney Plastic Packaging, Neenah (USA) 
PCR tubes, 0.2ml                 Biozym, Hess. Oldendorf 
Polypropylen reaction flask (15ml, 50ml)    Greiner, Nürtingen 
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Scalpel          Feather BLDG, Osaka, Japan 
Sterile needle (0.55 x 25mm)      Becton Dickinson, Fraga (ESP) 
Syringe (1ml)        Becton Dickinson, Fraga (ESP) 
Tissue Culture Flasks (25cm2, 75cm2)     Greiner, Nürtingen 
2.3 Instruments 
Centrifuge micro 22R                 Hettich 
Centrifuge 5417R           Eppendorf 
Electrophoresis equipment               Keutz, Reiskirchen 
Epoch Microplate Spectrophotometer                Biotek, USA 
Epoch Microplate Fluorescence photometer              Biotek, USA 
Illuminated magnifier         Eschenbach, Nürnberg 
Incubator for cell cultures               Thermo, USA 
L7-55 Ultracentrifuge            Beckman, USA 
Multifuge 3 S-R            Thermo Fisher Scientific, Langenselbold 
Nanodrop ND-100            Thermo Fisher Scientific, Langenselbold 
Peristaltic pump P-3               Pharmacia fine chemicals 
Odyssey™ Infrared Imaging SystemLI-COR®             Biosciences, Bad Homburg 
Optima L-100K Ultracentrifuge           Beckman, USA 
Sonifier Branson 102 C        Branson, Danbury, USA 
UV/Visible Spectrophotometers (in BSL3)             Biochrom, England 
2.4 Kits 
One-step RT-PCR kit              Qiagen, Hilden 
QIAquick Gel Extraction kit            Qiagen, Hilden 
QIAquick PCR Purification kit            Qiagen, Hilden 
RNeasy Mini kit              Qiagen, Hilden 
QIAamp Viral RNA Mini kit            Qiagen, Hilden 
2.5 Protein markers 
Page Ruler Prestained Protein Ladder        MBI-Fermentas, St.Leon-Rot 
DNA-marker GeneRulerTM 1kb DNA ladder        MBI-Fermentas, St.Leon-Rot 
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2.6 Antibodies 
2.6.1 Primary antibodies 
Anti-FPV serum from rabbit (10.03.92)  provided by Prof. Dr. Wolfgang Garten 
Institute of Virology,  
Philipps University Marburg, Germany 
Anti-H5N1 serum from rabbit (04.05.88)  provided by Prof. Dr. Wolfgang Garten 
Institute of Virology,  
Philipps University Marburg 
Anti-VSV serum from rabbit   provided by Prof. Dr. Georg Herrler 
Institute of Virology,  
University of Veterinary Medicine, 
Hannover 
2.6.2 Secondary antibodies 
Anti-rabbit serum (goat), IRDye 800         Rockland, Gilbertsville, USA 
Anti-mouse serum (donkey) Alexa Fluor 680       Molecular Probes, Karlsruhe 
Anti-tubulin (mouse)             Sigma-Aldrich, Deisenhofen 
Anti-rabbit from sheep, HRP      DAKO, Dänemark 
Anti-mouse from sheep, HRP      DAKO, Dänemark 
2.7 Enzymes 
Phusion High-Fidelity DNA polymerase      Thermo, Scientific 
Reverse transcriptase (RevertAid H Minus)     Fermentas, St.Leon-Rot 
RiboLock RNase inhibitor (Ribolock)      Fermentas, St.Leon-Rot 
Trypsin-TPCK            Sigma-Aldrich, Deisenhofen 
2.8 Primers 
Primer (oligonucleotides) was synthesized by Eurofins MWG Operon (Ebersberg). 
Primers for RT-PCR and sequencing (5’-3’) 
NA uni forward primer: TATTGGTCTTCAGGGAGCAAAGCAGGAGT 
NA uni reverse primer: ATATGGTCTCGTATTAGTAGAAACAAGGAGTTTTTT 
Bm-HA-1_forward primer: TATTCGTCTCAGGGAGCAAAAGCAGGGG 
Bm_NS-890_reverse primer: ATATCGTCTCGTATTAGTAGAAACAAGGGTGTTTT 
H7-400 reverse primer: CATGCACTAGTTGTTCCG 
H7-700 forward primer: CATTGGTTGATCTTGGATCC 
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H7-1300 forward primer: GCTGTATGAGCGAGTGAG 
FPV_NA_Seq_forward primer: GCATGGGTTGGCTAAC 
FPV_NA_Seq_reverse primer: CTCTTGCGTTCTCAATAT 
2.9 Viruses 
Institute of Virology, Phillips university Marburg, Germany 
Prof. Dr. Hans-Dieter Klenk and Prof. Dr. Wolfgang Garten 
A/chicken/fowl plague virus /Rostock/1934 (H7N1), FPV 
FPV_mutant_HAmono viruses 
Vesicular stomatitis virus, VSV  
Institute of Virology, Phillips University Marburg, Germany 
Dr. Mikhail Matrosovich 
A/Thailand/1(KAN-1)/2004 (H5N1), KAN-1 
2.10 Consumed materials for cell cultures 
Dulbecco’s Modified Eagle Medium (DMEM)       Gibco, Karlsruhe 
2 x Modified Eagle Medium (2xMEM)        Gibco, Karlsruhe 
Glutamine (100x)           Gibco, Karlsruhe 
Penicillin/Streptomycin (P/S)         Gibco, Karlsruhe 
Fetal calf serum (FCS)          Gibco, Karlsruhe 
Trypsin/EDTA           Gibco, Karlsruhe 
2.10.1 Cell culture medium 
DMEM growth medium     DMEM 
        10% FCS 
        1% glutamine 
        1% Penicillin/Streptomycin 
DMEM medium (w/o FCS)     DMEM 
        1% glutamine 
        1% Penicillin/Streptomycin 
Avicel suspension, 2.4% (w/v)   2.4g Avicel dissolved in 100ml dH2O 
Overlay medium     2xMEM and 2.4% Avicel solution (1:1) 
1% glutamine 
      1% Penicillin/Streptomycin 
       2% FCS 
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2.10.2 Cell lines 
MDCK  a subclone derived from the heterogenous parent Madin-Darby 
canine kidney cells, which was kindly provided by Prof. Dr. 
Wolfgang Garten, virology, Marburg 
Vero E6  isolated from kidney epithelial cells from an African green monkey, 
which was kindly provided by Prof. Dr. Wolfgang Garten, virology, 
Marburg 
2.11 Buffers 
 
PBSdef (pH 7.0) 
(Phosphate buffer deficient)  
NaCl 
KCl 
Na2HPO4 
KH2PO4 
dH2O 
8.00g 
0.20 g 
1.15g 
0.20g 
ad 1l 
 
PBS++ MgCl2 
CaCl2 
PBSdef 
0.1g 
0.13g 
ad 1l 
 
Anode buffer I (pH9.0) 1M Tris-HCl pH9.0 
ethanol 
dH2O 
300ml 
200ml 
ad 1l 
 
Anode buffer II (pH7.4) 1M Tris-HCl pH7.4 
ethanol 
dH2O 
25ml 
200ml 
ad 1l 
 
 
Cathode buffer (pH9.0) 
 
 
 
 
1M Tris-HCl pH9.0 
ε-Aminocapronic acid  
Ethanol 
dH2O 
 
25ml 
5.25g 
200ml 
ad 1l 
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Western Blot transfer buffer Tris 
Glycine 
Ethanol 
dH20 
 
 
5.8g 
2.9g 
200ml 
ad 1l 
10 x Running buffer pH 8.8 
(for SDS-PAGE)  
SDS 
Tris 
Glycine 
dH2O 
 
10g 
30g 
144g 
ad 1l 
 
4x SDS-sample buffer 0.5M Tris/HCl pH6.8 
SDS 
Glycerin 
2% bromphenol blue 
-mercaptoethanol dH2O 
4ml 
0.4 g 
4ml 
0.1ml 
0.4ml 
 
Neutral red stock solution 
 
Neutral red dye 
PBSdef 
40mg 
10ml 
 
Neutral red medium 
 
 
Neutral red stock solution 
DMEM medium (w/o 
FCS) 
100µl 
10ml 
 
 
Neutral red destain solution 
 
 
96% ethanol 
dH2O 
Acetic acid 
 
50% (v/v) 
49% (v/v) 
1% (v/v) 
 
Calcium-TBS- buffer 
(MUNANA assay) 
 
 
Stop buffer pH 10.7 
(MUNANA assay) 
NaCl 
Tris pH 7.0 
CaCl2 
 
Ethanol  
Glycine 
0.85% 
0.02M 
4mM 
 
25% 
0.1M 
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10 x TBE buffer, pH 8.0 Tris-base 
Boric acid 
0.5M EDTA, pH 8.0 
dH2O 
 
108g 
55g 
40ml 
ad 1l 
ELISA buffer 
(Immunostaining) 
Horse serum 
Tween-20 
PBSdef 
 
10% 
1% 
ad 1l 
0.05% Tween 
(Immunostaining) 
 
Tween-20 
PBSdef 
500µl 
ad 1l 
0.3% Triton-X  
(Immunostaining) 
Triton-X 
PBSdef 
3ml 
ad 1l 
 
2.12 Others 
SPF chicken eggs            Lohmann GmbH, Cuxhaven 
Chicken erythrocytes       Animal house, Philipps University Marburg 
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3. Methods 
3.1 Molecular and biological methods 
3.1.1 Antiviral compounds 
The neuraminidase inhibitor, oseltamivir carboxylate (GS4071), ribavirin, furin inhibitor 
dec-RVKR-cmk and synthetic peptidomimetic furin inhibitors were prepared as 10mM 
stock solutions in PBSdef. The trypsin protease inhibitor aprotinin was dissolved in H2O 
as 10mM stock solution. All inhibitors were stored at -20°C until use. Oseltamivir 
carboxylate is referred to as oseltamivir (Os) in this thesis (Structures of inhibitors are 
shown in Fig. S1 and Table S3).  
3.1.2 MTT viability assay 
The effect of inhibitors on the viability of MDCK cells was investigated by the MTT 
assay. MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, is a yellow 
substrate that can be reduced to purple formazan in living, metabolically active cells, 
but not in dead cells (Mosmann, 1983).  
MDCK cells were seeded in 96-well plates and grown to 100% confluence. Cells were 
incubated with inhibitor-containing Dulbecco’s Modified Eagle (DMEM) medium of 
different concentrations at 37°C. As a control, mock cells were incubated in medium 
without inhibitors. After a 24 or 48 hour-incubation, the inhibitor-containing medium 
was removed. Cells were washed with PBSdef and incubated with MTT solution 
(0.5mg/ml in PBSdef) for 2h at 37°C. After removal of the MTT solution, the formazan 
crystals were solubilised in 100µl dimethyl sulfoxide (DMSO) for 10min at room 
temperature. The absorbance of formazan solution in each well was quantified at 
570nm by an Epoch Microplate Spectrophotometer (Biotek, USA). For quantification, 
the MTT data was normalized against the untreated mock cells, of which the viability 
was set to 100%.  
3.1.3 Stability measurements of furin inhibitors with high performance liquid 
chromatography 
The stability of furin inhibitors was measured by high performance liquid 
chromatography (HPLC). The stocks of furin inhibitors were diluted in DMEM medium 
without FCS to final concentration of 30µM or 10µM and then incubated in the presence 
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or absence of MDCK cells at 37°C. At different time points after incubation,   0h, 24h, 
48h, 72h and 96h, 200µl cultured medium was collected and centrifuged at 30,000 rpm 
for 15min, of which 100µl were analyzed by analytical reverse phase HPLC. 
Quantitative determination of the inhibitor peak area yielded the amount of inhibitor 
remaining at each time point. The HPLC analyses were conducted by Prof. Dr. Torsten 
Steinmetzer, Institute of Pharmaceutical Chemistry, Philipps University Marburg 
(Becker et al., 2012). 
3.1.4 Sodium dodecyl sulfate polyacrylamide gel electrophoresis  
Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) is one of the 
most efficient methods for separating proteins by their electrophoretic mobility after 
binding of SDS to the proteins. The polyacrylamide gel was prepared according to the 
gel recipes. Protein samples were suspended in SDS sample buffer, containing sodium 
dodecyl sulfate (SDS) and β-mercaptoethanol, sonically treated for 30 to 60s and 
heated at 95°C for 5min. Insoluble material was removed by centrifugation at 
13000rpm for 10min (Laemmli, 1970). The gel was run at 150V (constant voltage) at 
room temperature until the bromophenol blue dye just ran off of the gel, which took 
about 1.5h. After electrophoresis, the gel was subjected to Western blot.  
 
Gel recipes (enough for 2 mini-gels): 
 
3. Methods 
41 
 
 
3.1.5 Western blots 
Western blot (WB) analysis is a ‘semi-dry’ blotting technique used for detecting a 
protein of interest from a great number of proteins (Kyhse-Andersen, 1984). After 
electrophoresis, proteins separated by SDS-PAGE were transferred from within the gel 
onto a nitrocellulose (NC) membrane (pore size 0.45µm) under a constant current of 
0.8mA/cm2 for about 1h. The membrane, gel and filter papers were soaked with WB-
transfer buffer and placed as showed below.  
 
Anode (+) 
3 x Whatman-filter paper soaked with WB-transfer buffer 
NC membrane 
SDS-PAGE gel 
3 x Whatman-filter paper soaked with WB-transfer buffer 
Cathode (-) 
 
To detect the bound proteins the unspecific protein-binding sites on the NC membrane 
were saturated by shaking in 7% milk buffer for 30min at room temperature. After, the 
membrane was incubated with the primary antibody for 1h at room temperature or 
overnight at 4°C. Before incubation with the secondary antibody, the membrane was 
washed with PBSdef three times. The secondary antibody was coupled with a 
Fluorophor (Alexa 680 or IRDye 800). After 1h incubation at room temperature, the 
membrane was again washed with PBSdef three times. Finally, the protein bands were 
visualized and quantified by the program Odyssey 2.01 (LI-COR Biosciences, USA). 
3.1.6 Viral RNA extraction  
Viral RNAs were isolated from the supernatants of infected cells using the QIAamp 
viral RNA Kit (Qiagen) according to the manufacturer’s instructions. 140µl virus 
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suspension was added to 560µl lysis buffer (buffer AVL from QIAamp viral RNA Kit 
containing 1% carrier RNA) and followed by 15s pulse-vortexing. Lysis of viral particles 
was completed after 10-minute incubation at room temperature and then it was mixed 
thoroughly with 560µl ethanol (100%). Afterwards, this homogeneous solution was 
subjected to the QIAamp Mini column, where the viral RNA was bound. After several 
wash steps, viral RNA was eluted with 50µl elution buffer (Buffer AVE from QIAamp 
viral RNA Kit) and stored at -80°C until use. The concentration of RNA was measured 
by photometer (NanoDrop ND-100).  
3.1.7 One-step reverse transcription polymerase chain reaction  
RNA samples were amplified by one-step reverse transcription polymerase chain 
reaction (one-step RT-PCR), which was conducted using the QIAamp One-step RT-
PCR Kit (Qiagen) according to the manufacturer’s instructions. The RNA template was 
first transcribed into complementary DNA (cDNA) by using a reverse transcriptase. The 
cDNA was then used as a template for PCR to amplify specific segments. The entire 
reaction from cDNA synthesis to PCR amplification was performed in one tube.  
 
RT-PCR mix (total volume 50µl): 
 
 
 
RT-PCR program:  
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3.1.8 Two-steps reverse transcription polymerase chain reaction 
3.1.8.1 Reverse transcription  
Extracted RNAs (800ng-2µg) were incubated with 1µl Uni influenza primer and dH2O 
(RNase free water) to a total volume of 12.5µl at 65°C for 5min then followed by a 
10min incubation on ice. After that, 4µl 5x RevertAid H Minus-buffer, 2µl dNTP, 0.5µl 
RevertAid H Minus reverse transcriptase and 0.5µl RibLock RNase inhibitor were 
added to this mixture and incubated at 25°C for 10min, 42°C for 60min and 70°C for 
10min. Synthesized cDNA was stored at -20°C before use. 
3.1.8.2 Polymerase chain reaction  
Polymerase chain reaction (PCR) was developed by Kary Mullis in 1983 (Mullis & 
Faloona, 1987). The PCR reaction was prepared as the following recipe in a total 
volume of 50μl.  
 
PCR mix (total volume 50µl): 
 
PCR program:  
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3.1.9 DNA electrophoresis 
Agarose gel electrophoresis is a commonly used analytical technique for DNA 
fragments separation. Agarose was dissolved to in 0.5% TBE buffer to a final 
concentration of 1%. Electrophoresis was performed in 0.5% TBE buffer at 120V for 
analysis and at 100V for DNA extraction. After incubation of the gel with ethidium 
bromide (EB), DNA fragments were visualized under the UV light (360nm).  
3.1.10 DNA fragment extraction and purification 
DNA fragments were extracted from an agarose gel using the QIAquick Gel Extraction 
Kit (Qiagen) according to the manufacturer’s instructions. DNA fragments were excised 
from the agarose gel and dissolved in solubilisation buffer (buffer QG from QIAquick 
Gel extraction kit). DNA-containing QG buffer was loaded to a QIAquick spin column 
to bind DNA. After several washing steps, DNA was eluted in 50µl H2O. The 
concentration of eluted DNA was determined by photometer (NanoDrop ND-100).  
3.1.11 DNA purification 
DNA purification was performed using the QIAquick PCR Purification Kit (Qiagen) 
according to the manufacturer’s instructions. DNA samples were thoroughly mixed with 
binding buffer (buffer PBI from QIAquick PCR purification Kit), then samples were 
added to a QIAquick spin column to bind DNAs. After several wash steps, DNA was 
eluted in 50µl dH2O.  
 
 
3.1.12 DNA-sequencing  
DNA sequencing was performed by the company Seqlab (Göttingen). 
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Sequencing mix: 
Plasmid-DNA or PCR product     300-400ng 
Primer (forward or reverse) (10pmol/µl)   1µl 
H2O        add to 15µl 
 
3.2 Cell culture methods 
To study the effects of synthesized furin inhibitors in vitro, MDCK and Vero E6 cells 
were used and cultured in DMEM growth medium supplemented with 1% 
penicillin/streptavidin (Pen/Strep, P/S), 1% glutamine and 10% fetal calf serum (FCS). 
Cells were grown in an incubator at 37°C with 5% CO2 and 80% humidity. 
Both MDCK and Vero E6 cells were grown in DMEM growth medium in T-75 flasks and 
were split twice a week. The growth medium was carefully poured off from the flasks 
and cells were washed once with 10ml PBSdef. Afterwards 3ml typsin/EDTA was added 
to the cells and incubated with the cells in the incubator at 37°C until the cells were 
completely detached from the flasks. Detached cells were then resuspended as single 
cells in 7ml fresh DMEM growth medium. The required amount of cell suspension was 
pipetted out of the flask and added into a new flask or cell culture plates.  
3.3 Virological methods 
3.3.1 Virus propagation in eggs  
Influenza virus, A/fowl plague virus/Rostock/1934 (FPV), A/Thailand/1(KAN-1)/2004 
(KAN-1) and FPV_mutant_HAmono were propagated in the allantoic cavity of 11-day-
old pathogen-free embryonated chicken eggs. The viability of each chicken embryo 
was checked before infection using an illuminator. To infect embryos, the blunt end of 
the egg was first disinfected with iodine and then a small hole was punched into the 
shell on the top of the egg. 200µl virus dilutions (virus stock 1:1000 diluted in PBSdef) 
were injected into the allantoic cavity using a 1ml syringe fitted with a 1 inch 
(dimenstion: 0.55 x 25mm) sterile needle and the hole in the shell was sealed with glue. 
Infected eggs were kept at 37°C in an egg incubator and checked daily to monitor the 
viability of each embryo until they were dead (24h to 48h p.i.). Eggs with dead embryos 
were kept at 4°C overnight. To harvest the virus, eggs were opened with forceps at the 
blunt end, and the allantoic fluids were collected using a 5ml syringe fitted with a 1.5 
inch, 21-gauge needle. Cell debris was removed by centrifugation at 4600 rpm for 
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20min. The virus-containing allantoic fluids were frozen in aliquots and stored at -80°C. 
The virus was titrated by plaque assay (see 3.3.4). 
3.3.2 Virus propagation in cell cultures 
Vesicular stomatitis virus (VSV) was propagated in Vero E6 cells. Confluent Vero E6 
in T-75 flask were washed with PBS++ and infected with VSV at a multiplicity of infection 
(MOI) of 0.1 (0.1 PFU/cell). This means 9.4 x 106 cells were infected with 9.4 x 105 
virions. After 1h of virus adsorption, the virus dilutions were removed and infected cells 
were washed with PBS++. 10ml DMEM medium (w/o FCS) was added to the flask. 
Infected cells were incubated at 37°C until more than 90% cytopathic effects (CPE) of 
cells appeared. Virus-containing supernatants were collected and cell debris was 
removed by centrifugation at 4600 rpm for 10min. The supernatants were frozen in 
aliquots and stored at -80°C, and virus titer was determined by plaque assay.  
3.3.3 Hemagglutination assay  
The hemagglutination assay (HA assay) is a simple, rapid method to quantify the 
influenza virus particles. In contrast to a plaque assay which only detects infectious 
viruses, both infectious and non-infectious viruses are detected by HA assay (Hirst, 
1942).  
V-bottomed 96-well plates were used in this assay. 50µl PBSdef was pipetted into each 
well and 50µl of virus sample was added to the first one. Virus was serially diluted 2-
fold in PBSdef from 1:2 to 1:212 and mixed with an equal volume of 0.5% chicken RBCs. 
Plates were incubated at 4°C for about 30min. As the HA protein of influenza virus is 
able to bind to sialic acid receptors on the surface of erythrocytes. The non-
agglutinated erythrocytes, which were not bound by viruses, sank to the bottom of the 
wells and formed distinct red buttons, whereas the virus-bound, agglutinated 
erythrocytes formed a lattice that coats the well. Virus titer was given in HAU/ml. The 
HA titer was the last dilution that showed complete hemagglutination activity.  
3.3.4 Plaque assay 
Plaque assay is a standard method used to determine the number of infectious virus 
in cell cultures. Infected cells are covered with a semi-solid medium, such as agar, 
carboxymethyl cellulose (CMC) or Avicel, which prevents the virus from spreading 
indiscriminately and thus causes a local infection. Each infectious virus particle forms 
a plaque (Matrosovich et al., 2006). 
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Cells were seeded in 24-well plates and grown to 100% confluence (MDCK cells for 
influenza virus and Vero E6 cells for VSV). Virus suspensions were serially diluted 10-
fold in DMEM medium (w/o FCS) and 200µl of virus dilution was added to each well. 
Infected cells were incubated at 37°C for 1h and then were washed once with PBSdef, 
before 400µl of 1.2% Avicel overlay-medium was added to each well. It should be noted 
that 1µg/µl trypsin-TPCK must be added to the overlay-medium for cells infected with 
FPV_mutant_HAmono viruses. After incubation at 37°C for 2 days, the overlay-medium 
were removed and cells were washed once with PBSdef. At 48h post infection (p.i.) 
500µl 4% paraformaldehyde (PFA) was added to each well. Plaque visualization was 
performed by immunostaining (3.3.6). Plaques were counted after staining and the 
virus titer was given in PFU/ml by using the following formula. 
 
N: number of plaques in each well  
df: dilution factor 
3.3.5 Plaque reduction assay 
A plaque reduction assay was used to determine the drug sensitivity of influenza 
viruses and was performed according to the protocol from Matrosovich et al. with 
modification (Matrosovich et al., 2006). Cells in 24-well or 6-well plates were inoculated 
with virus diluted to 50/70PFU. After 1h of virus adsorption, viral inoculums were 
replaced with 500µl (24-well plates) or 3ml (6-well plates) Avicel overlay medium 
containing serially diluted drugs. Plaque calculations were performed after incubation 
at 37°C for 2 (24-well plates) or 3 days (6-well plates). 
 
3.3.6 Immunostaining 
Infected cells were fixed with 4% PFA and permeabilized with 0.3% Triton X-100 in 
PBSdef at room temperature for 20min. Afterwards, cells were incubated with primary 
antibody for 1h followed by incubation with HRP-conjugated secondary antibody for 1h. 
Plaques or infected cells were visualized by incubating with peroxidase substrate 
TrueBlue (KPL) for 5-10min. Stained cells were washed with H2O to stop the reaction 
and then dried. Antibodies were diluted in freshly prepared ELISA buffer (see 2.11). 
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After incubation with primary and secondary antibody, cells were washed 3 times with 
0.05% Tween 20 buffer (Matrosovich et al., 2006).  
3.3.7 Cleavage of HA0 protein in the presence of furin inhibitors 
MDCK cells in a 24-well plate were infected with FPV at a high MOI of 100. After 1h 
incubation at 37°C, virus dilutions were removed and cells were washed with PBSdef. 
DMEM media (w/o FCS) containing different inhibitors at indicated concentrations were 
then added to each well. At 16 or 24h p.i., virus-containing supernatants and infected 
cells were collected and analyzed. Infected cells were scraped in PBSdef and pelleted 
by centrifugation at 13000 rpm for 10min. Cell pellets were resuspended in 4x SDS 
sample buffer and prepared before subjection to the SDS-PAGE and Western blot (see 
3.1.4 and 3.1.5). 
Virus-containing supernatants were centrifuged at 10000 rpm for 10min to remove the 
cell debris. The released virus in the supernatant (after initial centrifugation) was then 
concentrated by ultracentrifugation at 450000 rpm at 4°C for 1h. Virus pellets were 
resuspended in 4 x SDS sample buffer and prepared before subjected to the SDS-
PAGE and Western blot (3.1.4 and 3.1.5). 
3.3.8 Virus spread in the presence of inhibitors 
MDCK cells were seeded in 24-well plates and grown to 100% confluence. Cells were 
infected with FPV or KAN-1 virus at a low MOI of 0.001 for 1h at 37°C. After infection, 
virus dilutions were removed and unbound viruses were washed off with PBSdef. Fresh 
DMEM medium (w/o FCS) containing a furin inhibitor at indicated concentrations was 
added to the cells. For combination treatment, infected cells were treated with furin 
inhibitor, oseltamivir and ribavirin at various concentrations. As a control, infected cells 
were incubated in DMEM medium (w/o FCS) without inhibitors. 24h after infection, 
infected cells were washed once with PBSdef, fixed with 4% PFA and immunostained 
with anti-FPV antiserum (see 3.3.6). 
3.3.9 HPAIV multicycle replication in the presence of a single inhibitor 
MDCK cells in 24-well plates were infected with FPV or KAN-1 virus at an MOI of 
0.0001. Viral inoculums were removed 1h after virus adsorption and then unbound 
virus particles were washed off with PBSdef. DMEM medium (w/o FCS) containing furin 
inhibitor MI-701, oseltamivir or ribavirin at different concentrations, were added to each 
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well, respectively. At 18h, 24h, 48h, 72h and 96h p.i. virus-containing supernatants 
were collected and titrated by plaque assay (see 3.3.4). 
3.3.10 Control inhibition assay using FPV mutant 
MDCK cells were seeded in 24-well plates and grown to more than 90% confluency. 
Cells were infected with FPV_mutant_HAmono at an MOI of 0.0001. After 1h of virus 
adsorption, unbound viruses were washed off with PBSdef. To support the 
FPV_mutant_HAmono virus multicycle replication, infected cells were incubated in 
DMEM medium (w/o FCS) containing 1µg/ml Trypsin-TPCK. For inhibition assay, 
stocks of furin inhibitor MI-701, trypsin inhibitor aprotinin and oseltamivir were diluted 
in DMEM medium (w/o FCS) containing 1µg/ml Trypsin-TPCK and added to infected 
cells. As a control, infected cells were incubated in the absence of inhibitors. At 24h, 
48h and 72h p.i., viral supernatants were collected and viral titer was determined by 
plaque assay.  
3.3.11 Combination treatment of HPAIV infection  
To investigate the inhibitory efficacy of furin inhibitor MI-701 in combination with 
oseltamivir and ribavirin, MDCK cells were infected with FPV or KAN-1 virus at an MOI 
of 0.0001. After 1h of virus adsorption, unbound viruses were washed off and cells 
were treated with furin inhibitor MI-701 and oseltamivir in combination or together with 
ribavirin in triple combination at different concentrations. Virus-containing supernatants 
were collected at 18h, 24h, 48h, 72h and 96h p.i. and virus titer was determined by 
plaque assay (see 3.3 4).  
3.3.12 Time of inhibitor addition 
The influence of therapeutic time on the inhibitory activity of a drug against HPAIV was 
investigated by a time-based approach. MDCK cells in 24-well plates were grown to 
100% confluence and infected with FPV at an MOI of 0.001. Virus inoculums were left 
on the cells for 1h. Cells were then washed with PBSdef and treated with furin inhibitor 
MI-701 as a single drug or together with oseltamivir and ribavirin in triple combination. 
Inhibitor treatment was conducted immediately after infection (0h p.i.) or at 6h, 14h, 
20h or 30h p.i.. At 48h p.i., cell culture supernatants were collected for virus titration 
and cells were fixed with 4% PFA. Infected cells were visualized by immunostaining 
using anti-FPV anti-sera (see 3.3.6).  
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3.3.13 Neutral red uptake assay  
Neutral red uptake assay (NR assay) is widely used for determination of viral 
cytopathogenicity and treatment effectiveness, as it provides a quantitative estimation 
of the number of viable cells in a culture. Neutral red (NR) dye penetrates the cell 
membrane by non-ionic passive diffusion and concentrates in lysosomes, where the 
pH is lower than in the cytoplasm. When the cells are damaged or dead, the lysosomes 
can no longer bind the dye. Therefore, the retained amount of dye is proportional to 
the number of viable cells. 
The NR assay was modified from the protocol from Repetto et al. (Repetto et al., 2008). 
Medium was removed from the cells in 96-well plates and 100µl NR medium, which 
was prepared one day in advance from 4mg/ml NR stock solution, was carefully added 
to each well. After incubation for 2h at 37°C with 5% CO2, NR medium was removed 
and cells were washed with PBSdef. To extract the dye from living cells, 100µl NR 
destain solution was added to each well and the plate was incubated on a shaking 
device for 10min. The amount of NR taken up by cells was quantified at 562nm using 
a spectrophotometer. 
3.3.14 Inhibitor efficiency calculation  
To access the 50% effective concentration (EC50) of inhibitors, MDCK cells were 
confluently grown in 96-well plates and infected with FPV at an MOI of 0.0001. After 
1h, virus inoculums were removed and cells were washed with PBSdef. A stock of furin 
inhibitor MI-701 was serially diluted in DMEM medium (w/o FCS) and was then added 
to the cells. The plates were incubated at 37°C. Virus control cells were left untreated 
and mock cells were not infected with virus. At 48h p.i. the extent of CPE in each well 
was determined by neutral red uptake assay (3.3.13). The EC50 calculations were 
conducted by normalizing the NR data for each well against the mock control and virus 
control, which were set to 100% and 0, respectively. Normalized NR data were plotted 
as percent virus infection inhibition versus inhibition concentration. The data points 
were then fitted using five-parameter curve fitting in Graphpad Prism (Graphpad 
Software, La Jolla, CA) to obtain the EC50. 
3.3.15 Synergistic inhibition analysis  
To investigate the interactions of MI-701 and oseltamivir and ribavirin, MDCK cells 
were seeded in 96-well plates and infected with FPV at an MOI of 0.0001. After 1h for 
virus adsorption, 100µl DMEM medium (w/o FCS) containing furin inhibitor MI-701 and 
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oseltamivir in combination or together with additional ribavirin in triple combination was 
added to each well (experimental design in 96-well plate see Fig. S6 in supplementary). 
48h after infection the extent of virus caused CPE in each well was determined NR 
assay (see 3.3.13).  
The synergy analysis was calculated using the MacSynergy III program, which is an 
Excel worksheet. It was developed by Prichard and Shipman based on the 
MacSynergy II program (Prichard & Shipman, 1990; Prichard et al., 1993). Data were 
presented as contour plots. The theoretical additive interactions were calculated from 
the concentration-response curves of single inhibitor and subtracted from the 
experimentally determined inhibition to reveal different drug-drug interactions: additive, 
no differences between theoretical additive interactions and observed inhibition; 
synergy, the theoretical additive interactions is less than the experimental inhibition; or 
antagonism, which indicats the experimentally determined inhibition was greater than 
expected. All the values were derived from the mean of 3 replicates and presented at 
95% confidence, which eliminates insignificant deviations from the additive surface. 
3.3.16 Vesicular Stomatitis Virus control infection experiment 
Vero E6 cells in 24-well plate were infected with VSV at an MOI of 0.0001. After 1h of 
virus adsorption, viral inoculums were removed and unbound viruses were washed off. 
Fresh DMEM medium (w/o FCS) containing furin inhibitor MI-701, oseltamivir alone or 
in combination at indicated concentration was added to cells. As a control, infected 
cells were incubated with DMEM medium (w/o FCS) in the absence of inhibitors. At 
different time points, released viruses were titrated by plaque assay using Vero cells 
(see 3.3.4). 
3.3.17 Control infection experiment with apathogenic influenza virus 
MDCK cells were infected with FPV_mutant_HAmono at an MOI of 0.0001. After 1h of 
virus adsorption, unbound virus particles were washed off. DMEM medium (w/o FCS) 
containing 1µg/ml Trypsin-TPCK and different inhibitors, furin inhibitor MI-701, 
aprotinin or oseltamivir, at indicated concentrations were added to the cells. As a 
control infected cells were incubated without inhibitor treatment. At 24h, 48h and 72h 
p.i. virus-containing supernatants were collected and titrated by plaque assay (see 
3.3.4).  
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3.3.18 Serial propagation of FPV in the presence and absence of antivirals 
FPV was serially passaged in the presence or absence of antivirals to determine the 
development of drug-resistant variants. The protocol was conducted according to 
Ilyushina et al. with modification (Ilyushina et al., 2006) (Fig. 3.1). MDCK cells in T-25 
flasks were infected with FPV at a low MOI of 0.001 in DMEM medium (w/o FCS). The 
virus was allowed to adsorb for only 30min at 37°C to minimize the probability of 
selecting virus with weak affinity for host receptors. The inoculums were removed after 
virus adsorption and the cells were washed with PBSdef. After that, fresh DMEM 
medium (w/o FCS) containing furin inhibitor MI-701 and oseltamivir alone or in 
combination was added to the cells. Cells were then incubated at 37°C until greater 
than 90% CPE appeared. At that time, the virus-containing supernatants from drug 
treated infected cells were collected, clarified of cellular debris by centrifugation at 
1800 rpm for 5min at 4°C and stored at -80°C. Virus titer of each sample was 
determined by plaque assay in MDCK cells after each passage. For subsequent 
passages, cells were infected with the supernatant from the previous passage at an 
MOI of 0.001. The concentration of oseltamivir and furin inhibitor MI-701 in the first 
round of selection was chosen at a low level, at which virus replication in cell cultures 
was about 50% inhibited. The concentrations of both inhibitors were doubled in the 
each subsequent passage. Every few passages, plaque reduction assay were 
performed to examine the susceptibility of virus to the correspondent inhibitor. 
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Fig.3.1: Scheme of propagation of FPV in the presence and absence of antivirals in MDCK cells. MI=MI-701; Os=oseltamivir; Ø = no drug. 
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3.3.19 Virus inactivation  
Research on highly pathogenic influenza virus must be conducted under biosafety 
level 3 (BSL-3) containment conditions. The limited working condition under BSL-3 
hampers the timely characterization of such viruses. β-Propiolactone inactivation 
allows for better and more efficient studies on such viruses under biosafety level 2 
(BSL-2) conditions (Jonges et al., 2010). 
Both egg- and cell-grown viruses were incubated with 0.05% β-propiolactone at 4°C 
for 2 days. 2% HEPES buffer was extra added to cell-grown viruses. After incubation, 
inactivated viruses were subjected to blind passages in MDCK cells twice. As a control, 
viruses without treatment with β-propiolactone were passaged parallel in MDCK cells.  
For blind passage, confluent MDCK cells in T-25 flasks were incubated with DMEM 
medium (w/o FCS) containing 10% β-propiolactone treated viruses at 37°C. After one 
week, 500µl the culture supernatants was used as inoculums for the second passage 
on MDCK cells and the cells were incubated at 37°C for one week. Harvested culture 
supernatants were titrated by plaque assay to confirm inactivation. After confirmation, 
these viruses were allowed to be exported out of BSL-3.  
3.3.20 Determination of neuraminidase activity  
To compare the susceptibility of FPV variants to oseltamivir, 2’-(4-methylumbelliferyl)-
α-D-N-acetylneuraminic acid (MUNANA)-based enzyme inhibition assay was used. 
MUNANA is a fluorometric substrate, which is cleaved by NA to yield free 4-
methyumbelliferone (4-MU). The fluorescence of released 4-MU is expressed in 
relative fluorescence units (RFU) for NA activity determination (Potier et al., 1979; 
Marathe et al., 2013).  
FPV wild type and variants were diluted in calcium-TBS buffer. The viral dilution, which 
generates an equivalent RFU to that generated by 10μM of 4-methyumbelliferone 
sodium salt (4-MUSS) was selected for NA enzyme inhibition assay and can be 
evaluated by a 4-MUSS standard curve. 
To generate a 4-MUSS standard curve, 100µM 4-MUSS working solution was prepared 
from 0.1mM stock solution and then serially diluted in 2-fold dilution in stop buffer. 200μl 
of each dilution of 4-MUSS was added to a black, flat-bottomed 96-well plate. The 
fluorescence activity of each dilution of 4-MUSS was measured with an Epoch 
Microplate Spectrophotometer (Biotek, USA), using an excitation wavelength of 360nm, 
an emission wavelength of 460nm and was plotted against 4-MU concentrations. 
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To determine the NA activity, FPV wild type and mutants were serially diluted 2-fold in 
MUNANA buffer and 40µl of each dilution of viruses were added to a black, flat-
bottomed 96-well plate. Wells containing only calcium-TBS buffer acted as blank 
control. After that 1mM MUNANA substrate was prepared from 4mM stock solution in 
MUNANA buffer and 10µl of MUNANA substrate was added to each well, including 
blank control wells. The buffer was mixed with the virus dilutions by pipetting up and 
down several times. The plates were then sealed with parafilm and incubated at 37°C 
for 60min. To stop the reaction, 150µl of stop buffer was added to each well and the 
released 4-MU was measured with an Epoch Microplate Spectrophotometer (Biotek, 
USA), using an excitation wavelength of 360nm and an emission wavelength of 460nm. 
The RFU was plotted against virus dilutions, in which the mean of blank controls value 
was subtracted. The virus dilution which produced the equal level of RFU to 10µM of 
4-MUSS was determined and was used in NA enzyme inhibition assay.  
3.3.21 Virus susceptibility to oseltamivir  
FPV viruses were diluted in MUNANA buffer. This dilution produced an equal level of 
RFU to 10µM 4-MUSS (3.3.21). Then 4000nM oseltamivir was prepared from 10mM 
stock solution and was diluted four-fold in MUNANA buffer. 20µl of each dilution was 
added to each well and mixed thoroughly. Wells contained virus dilutions or only 
MUNANA buffer as blank or virus control, respectively. The plate was sealed and 
incubated at 37°C for 30min, then 10µl of 1mM MUNANA substrate was added to each 
well and the plate was resealed and incubated at 37°C for 60min. The reaction was 
terminated by adding 150µl stop buffer to each well. Released 4-MU was measured 
with Epoch Microplate Spectrophotometer (Biotek, USA), using an excitation 
wavelength of 360nm and an emission wavelength of 460nm. The 50% inhibitory 
concentration (IC50) of the NA inhibitor was the concentration of oseltamivir that 
produced 50% RFU of virus control value. This was determined by plotting the dose-
response curve of inhibition of NA against RFU. Values were the means of four 
independent determinations. 
 
3.3.22 Growth kinetic of FPV mutants 
The growth kinetic of FPV wild type and FPV_NA mutants, FPV_NAH275Y, FPV_NAN295S 
and FPV_NAI223M/P272H viruses were evaluated using MDCK cells in 6-well plates. 
Confluent MDCK cells were infected with virus at an MOI of 0.0001. After 1h incubation 
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at 37°C, viral inoculums were replaced with 3ml fresh DMEM medium (w/o FCS). At 
14h, 24h, 48h, 72h p.i., virus-containing supernatants were collected for virus titer 
determination using plaque assay (see 3.3.4).  
3.3.23 Effect of MI-701 on replication of FPV mutants 
MDCK cells were infected with FPV wild type and FPV mutants, FPV_NAH275Y, 
FPV_NAN295S and FPV_NAI223M/P272H, at an MOI of 0.0001. After 1h, virus dilutions were 
removed and cells were washed with PBSdef. Infected cells were treated with 50µM MI-
701 or left untreated. At 18h, 24h, 48h and 72h p.i. released viruses were titrated by 
plaque assay (see 3.3.4).  
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4. Results 
4.1 Screening of furin inhibitors 
The emergence of drug-resistant viruses is a big challenge for the treatment of 
influenza infection with antivirals. Therefore, searching for novel antiviral targets is 
urgently needed to control and prevent annual influenza epidemics or pandemics.  
Since the cleavage of HA of HPAIV by furin is a prerequisite for virus replication (see 
1.3.1), furin inhibitors emerged to be potential therapeutic agents for treatment of 
HPAIV infection. In this chapter, more than 20 synthesized peptidomimetic furin 
inhibitors were examined for their cytotoxicity and potential inhibitory efficiency against 
HPAIV in cell culture.  
4.1.1 Determination of cytotoxicity  
Before analyzing antiviral efficacy of these compounds, their cytotoxicity was examined 
by MTT assay (data is shown in Table S4 in supplementary). MDCK cells were grown 
to 100% confluency and incubated with inhibitors at two different concentrations, 25µM 
and 50µM. The viability of treated cells was measured at 24h and 48h after incubation. 
Most compounds, both at the lower concentration of 25µM and at the higher 
concentration of 50µM proved to be non-toxic for the cells, except the compounds MI-
232 and MI-233. The addition of these compounds caused 40% and 80% loss of 
viablitiy at the concentration of 25µM and 50µM, respectively. Compounds MI-259 and 
MI-283 exhibited no cytotoxic effects at the concentration of 25µM, but caused more 
than 50% viability reduction at the concentration of 50µM (Fig. 4.1).  
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Fig. 4.1: Cytotoxicity determination of different furin inhibitors in vitro. The cytotoxic effects of 
synthesized furin inhibitors were determined by MTT assay. MDCK cells were treated with different 
compounds at 25µM (A) or 50µM (B), respectively. Mock cells were incubated in the absence of 
inhibitors. After incubation at 37°C for 24h or 48h, cells were further incubated with 0.5mg/ml MTT for 
2h at 37°C.The produced formazan was eluted in DMSO and quantified by measuring at wavelength 
570nm by a spectrophotometer. Sturcture of each inhibitor is shown in Table S3 in supplementary. 
 
Compound MI-701 was well tolerated by the MDCK cells up to 400µM (Fig. 4.2). As 
expected, presence of oseltamivir did not affect the viability of the cells, even at the 
concentration of 400µM, whereas cells which were incubated with more than 100µM 
of ribavirin for 48h lost approximately 30% viability. Moreover, the furin inhibitor dec-
RVKR-cmk (Stieneke-Gröber et al., 1992; Garten et al., 1994), which was used as a 
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reference inhibitor, also induced a slightly cytotoxic effect at 50µM (ca. 10%) when 
compared with untreated cells. 
 
 
 
Fig. 4.2: Dose-dependent cytotoxicity of different inhibitors. The cytotoxic effects of oseltamivir and 
ribavirin were determined by MTT assay in parallel. MDCK cells were treated with different inhibitors at 
indicated concentrations, ranging from 0.1 to 400 µM, respectively. Control cells were incubated in pure 
DMEM medium (w/o FCS) in the absence of inhibitors. After incubation at 37°C for 24h (A) or 48h (B), 
cells were further incubated with 0.5mg/ml MTT for 2h at 37°C. Produced formazan was dissolved in 
DMSO and quantified by measuring at wavelength 570nm by a spectrophotometer. For quantification, 
the viability of control cells was set to 100%. (n = 4).  
 
4.1.2 Determination of stability  
To determine the stability of selected furin inhibitors, compounds MI-701 and MI-299 
were selected and prepared in DMEM medium (w/o FCS) at the concentrations of 
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10µM and 30µM. Compounds at indicated concentrations were incubated at 37°C in 
the presence or absence of MDCK cells for 24h, 48h, 72h and 96h. After incubation, 
the supernatant of each sample was collected and cell debris was removed. Samples 
were then analysed by Prof. Dr. Torsten Steinmetzer using analytical HPLC at the 
Institute of Pharmaceutical Chemistry, Philipps University Marburg.  
Both compounds were stable in pure medium up to 96h (Fig. 4.3), whereas in the 
presence of MDCK cells the amount of both compounds decreased in a time 
dependent manner. The amount of compound MI-701 was reduced by approximately 
30% and 50% when its initial concentration was 30µM and 10µM, respectively, while 
compound MI-299 was reduced to 40% and 50%.  
 
 
 
Fig. 4.3: Stability measurement of furin inhibitors. Compound MI-299 (A) and MI-701 (B) at 10 and 
30µM were incubated in the presence or absence of MDCK cells in DMEM medium (w/o FCS) or in pure 
DMEM medium (w/o FCS) at 37°C. 24h, 48h, 72h and 96h after incubation, medium that contained MI-
701 was collected and cleared by centrifugation at 30,000rpm at 4°C for 15min. Supernatants were 
stored at -80°C before being analyzed by HPLC, which corresponds to approximately 3.7µg for the 
30µM solution and to 1.2µg for the 10µM solution. Δ = 30µM in MDCK cell cultures; ▲ = 30µM in pure 
medium; ○ = 10µM in MDCK cell cultures; ● = 10µM in pure medium. Figures were taken from Becker 
et al., 2012 with modification. 
 
4.1.3 Cleavage of HA0 in the presence of furin inhibitors 
In order to analyze the cleavage of HA of HPAIV in the presence of furin inhibitors, 
MDCK cells were infected with A/chicken/fowl plague virus/Rostock/1934 (H7N1) (FPV) 
at a high MOI of 100. Infected cells were treated with different furin inhibitors at the 
concentration of 50µM. As a control, infected cells were left untreated. At 16h p.i. 
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approximately 90% cytopathic effect (CPE) was detected and infected cells were 
collected and suspended in SDS sample buffer containing β-mercapthoethanol. Viral 
protein samples were loaded onto an SDS-PAGE gel and were analyzed by Western 
blot (Fig. 4.4).  
 
 
Fig. 4.4: Cleavage of HA in the presence of different furin inhibitors (A) and quantification of HA 
cleavage inhibition (B). MDCK cells were infected with FPV at an MOI of 100. After virus adsorption, 
infected cells were treated with different furin inhibitor at a concentration of 25µM or without inhibitor 
treatment. At 16h p.i. cell lysates were collected and subjected to SDS-PAGE under reducing conditions 
and Western blot analysis using antiserum against FPV and an anti-tubulin antibody as a loading control. 
Furin inhibitor dec-RVKR-cmk was used as a reference inhibitor in this experiment. (B) For quantification, 
the intensity of each HA0 band was standardized against that of the β-tubulin bands. The normalized 
intensities of HA0 obtained in cells treated with 50µM MI-701 were set to 100%. The intensities of protein 
bands were measured by the program Odyssey 2.1. Toxic inhibitors were not quantified.  
 
Viral HA0 proteins were almost completely cleaved into HA1 and HA2 subunits in the 
absence of furin inhibitor (Fig. 4.4). Treatment of cells with 50µM compounds MI-232, 
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MI-233, MI-258, MI-259 and MI-283 led to less production of viral proteins (structures 
in Table S3 in supplementary). This indicated that these compounds were toxic for 
cells and thus affected the growth of FPV in cells. After quantification (Fig. 4.4B) it was 
observed that treatment with furin inhibitors resulted in detection of more than 20% 
precursor HA0, and the compounds MI-227, MI-230, dec-RVKR-cmk MI-299 as well 
as MI-701 significantly inhibited the cleavage of HA0 from 60% to 90%, among which 
compound MI-701 was the most potent.  
4.2 Inhibitory efficacy of furin inhibitor MI-701 against HPAIV 
infection 
4.2.1 Cleavage of HA0 in the presence of inhibitor MI-701  
The inhibitory effect of the compound MI-701 on the cleavage of HA protein was the 
most potent and therefore was further studied. MDCK cells were infected with FPV at 
a high MOI and treated with different concentrations of furin inhibitor MI-701. Cell 
lysates and virus-containing supernatants were collected at 24h p.i. and then subjected 
to SDS-PAGE and Western blot (Fig. 4.5). In comparison with untreated cells, 
treatment with MI-701 not only resulted in accumulation of uncleaved HA0 proteins in 
cell lysates but also led to release of non-infectious virus particles, which contains 
inactivated HA proteins. The amount of HA0 in both cell lysates and supernatants 
increased with increasing concentrations of inhibitor MI-701, ranging from 0.5µM to 
50µM. The inhibitory effects of MI-701 at the different concentrations were quantified 
as described in Fig. 4.5. The inhibitiory effects of MI-701 on HA cleavage was obviously 
dose-dependent. The HA cleavage of HPAIV KAN-1 virus in the presence of MI-701 
was also investigated, which was strongly inhibited in the presence of MI-701, ranging 
from 0.1µM to 50µM. Treatment of 1µM of MI-701 resulted in detection of more than 
50% of the uncleaved form of HA (Fig. S2 in supplementary).  
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Fig. 4.5: Cleavage of HA0 in the presence of inhibitor MI-701 at various concentrations. MDCK 
cells were infected with FPV at an MOI of 100. After virus adsorption, infected cells were treated with 
MI-701 at concentrations of 0.5, 1, 10, 25 and 50µM, respectively, or without inhibitor treatment. At 24h 
p.i. cell lysates (A) and virus-containing supernatants (B) were collected and subjected to SDS-PAGE 
and Western blot. Viral protein bands were visualized using antiserum against FPV and anti-tubulin 
antibody as loading control. For quantification, the intensity of each HA0 band was standardized 
correlating to the β-tubulin bands (A) or NP bands (B) and the normalized intensity of HA0 obtained in 
cells treated with 50µM MI-701 was set to 100%. The intensities of protein bands were performed by 
the program Odyssey 2.1.  
 
4.2.2 Virus spread in the presence of inhibitor MI-701 
It has been shown in the last chapter that treatment with compound MI-701 efficiently 
inhibited the cleavage of HA0 of FPV. The inhibitory potency of the compound MI-701 
against the secondary infection of non-infected neighbouring cells was examined. 
MDCK cells were infected with FPV or KAN-1 virus at a low MOI. Infected cells were 
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incubated with an increasing concentration of inhibitor MI-701. Infected cells were fixed 
at 24h p.i. and were visualized by immunostaining (Fig. 4.6).   
 
 
 
Fig. 4.6: Virus spread in the presence of furin inhibitor MI-701. MDCK cells were infected with FPV 
or KAN-1 virus at an MOI of 0.001. Infected cells were treated with compound MI-701 at concentration 
of 0.5µM, 1µM, 5µM, 10µM, 25µM or 50µM or incubated without inhibitor treatment. At 24h p.i. cells 
were fixed with 4% PFA and then infected cells were immunostained against anti-FPV antibody and 
HRP-conjugated anti-rabbit secondary antibody.  
 
Without treatment of MI-701 almost all the cells were infected due to the secondary 
infection, whereas treatment of MI-701, ranging from 5µM to 50µM, protected the 
neighbouring non-infected cells from secondary infection, especially in cells treated 
with 25µM and 50µM MI-701, where only slight spread of infections was observed. 
However, treatment with MI-701 less than 5µM was not able to suppress the spread of 
infection.  
4.2.3 Inhibitory efficacy of inhibitor MI-701 on HPAIV multicycle replication 
HPAIV FPV and KAN-1 virus were employed to explore the inhitory efficacy of MI-701 
on virus replication in cell cultures. Two additional antivirals, oseltamivir and ribavirin, 
were examined in parallel in this experiment. The neuraminidase inhibitor oseltamivir 
inhibits virus release by inhibiting the activity of neuraminidase. Ribavirin interferes with 
virus replication by inhibiting a key enzyme inosine 5’-monophosphate (IMP) 
dehydrogenase that is involved in viral RNA synthesis (De Clarcq, 2006). 
 
4. Results 
65 
 
 
 
Fig. 4.7: Inhibition of HPAIV multicycle replication in cell cultures. MDCK cells were infected with 
FPV (A) of KAN-1 virus (B) virus at an MOI of 0.0001. Virus inoculum was removed after 1h and then 
cells were washed with PBSdef and incubated with inhibitor MI-701 at the concentration of 10µM, 25µM 
and 50µM, or oseltamivir at the concentration of 0.01µM, 0.1µM and 0.5µM or ribavirin at the 
concentration of 10µM and 25µM, respectively. As a control, infected cells were incubated in infection 
medium without inhibitor. At indicated time points, 18h, 24h, 48h, 72h and 96h p.i., virus-containing 
supernatants were collected and virus titer was determined by plaque assay. (n ≥ 3) 
 
MDCK cells were infected with FPV or KAN-1 virus at a low MOI of 0.0001 and then 
treated with inhibitor MI-701, oseltamivir or ribavirin at indicated concentrations, 
respectively (Fig. 4.7 A and B). Virus titer at indicated time points was determined by 
plaque assay. As shown in Fig. 4.7 both FPV and KAN-1 virus rapidly replicated in 
untreated cells and reached highest titer of 107 and 108 PFU/ml at 24h p.i. and 48h p.i. 
respectively. As expected, oseltamivir and ribavirin efficiently inhibited FPV and KAN-
1 virus propagation. Inhibitor MI-701 suppressed the virus replication in a dose-
dependent manner (Fig. 4.7 A and B). Treatment with 10µM MI-701 resulted in 
approximately 100-fold virus titer reduction in FPV-and KAN-1 virus-infected cells at 
24h p.i.. In the presence of 50µM of inhibitor MI-701 the release of both viruses were 
delayed for 18h and virus yields at 24h p.i. were reduced approximately 1,000,000-fold.  
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4.2.4 Specificity of furin inhibitor MI-701 
The FPV_mutant_HAmono virus was derived from FPV with the HA cleavage site 
PSR↓GLF, which is proteolytic activated by trypsin or trypsin-like proteases. Thus, the 
replication of FPV_mutant_HAmono virus should be inhibited by addition of the trypsin 
inhibitor aprotinin and neuraminidase inhibitor oseltamivir, but not by a furin inhibitor. 
MDCK cells were infected with FPV_mutant_HAmono virus at a low MOI. Cells were 
then incubated with furin inhibitor MI-701, oseltamivir and aprotinin at indicated 
concentrations, respectively. At indicated time points, virus samples were collected 
and titrated by plaque assay (Fig. 4.8). 
 
 
 
Fig. 4.8: Inhibition of FPV_mutant_HAmono multicycle replication in cell cultures. MDCK cells were 
infected with FPV_mutant_HAmono virus at an MOI of 0.0001. After 1h, viral inoculums were removed 
and unbound virus particles were washed off with PBSdef. Infected cells were incubated DMEM medium 
(w/o FCS) containing 1µg/ml trypsin-TPCK and different inhibitors: 10µM and 50µM MI-701, 10µM 
aprotinin and 0.5µM oseltamivir. At 24h, 48h and 72h p.i. virus-containing supernatants were collected 
and the virus titer was determined by plaque assay. (n = 2) 
 
As expected, the virus yields in aprotinin- and oseltamivir-treated cells were one 
million- and thousand-fold reduced, respectively, at 24h p.i. in comparison with those 
in cells without treatment and treatment of MI-701 did not inhibit the replication of 
FPV_mutant_HAmono virus. The virus titer in cells treated with either 10µM MI-701 or 
50µM MI-701 was comparable to that of non-treated cells. It demonstrated that the 
compound MI-701 was specific furin-targeting inhibitor (Fig. 4.8). 
4. Results 
67 
 
4.3 Combination therapy against HPAIV 
Combination chemotherapy has been well studied and developed to treat cancer and 
diseases caused by infectious pathogens, such as human immunodeficiency virus type 
1 (HIV-1). Combination of two or more drugs that achieve the same effects through 
different mechanisms may enhance the therapeutic efficiency more than treatment with 
single drug. In chapter 4.1, furin inhibitor MI-701 was proved to be a promising anti-
influenza agent, which potently inhibited the cleavage of HA0 and hence resulted in 
poor virus spread and replication in cell cultures. Therefore, it is of great interest to 
know, if the anti-HPAIV efficacy would be further enhanced when furin inhibitor MI-701 
is combined with other antivirals.  
Furin inhibitor MI-701 was combined with neuraminidase inhibitor oseltamivir in or 
together with ribavirin in triple combination for treatment the infection of HPAIV in cell 
cultures. Drug-drug interaction was evaluated by using the MacSynergy III program 
(Prichard & Shipman, 1990). Oseltamivir used in this thesis is its active form oseltamivir 
carboxylate. 
4.3.1 Cell viability in the presence of different drugs 
The combination of multi-drugs with different functions may induce additional toxicity 
that is not observed by using either drug alone (Pirrone et al., 2011). Therefore, it is 
important to evaluate the toxicity of combined MI-701, oseltamivir and ribavirin to the 
cells. MDCK cells were treated with a combination of MI-701 and oseltamivir or 
together with ribavirin in triple combination for 24h and 48h, respectively (Fig. 4.9). All 
treated cells preserved similar viability to untreated cells, indicating that treatment with 
MI-701, oseltamivir and ribavirin in combination at indicated concentrations did not 
induce toxic effects to the cells.   
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Fig. 4.9: Cytotoxicity of MI-701 in combination with antiviral agents. The cytotoxic effects in the 
presence of drugs in combinations were determined by MTT assay. MDCK cells were incubated with 
50µM MI-701 (MI) alone, in combination with 0.5µM oseltamivir (Os) or together with 0.5µM oseltamivir 
and 25µM ribavirin (Rib). As a control, cells were incubated in DMEM medium (w/o FCS) in the absence 
of inhibitor. After incubation at 37°C for 24h or 48h, cells were further incubated with 0.5mg/ml MTT for 
2h at 37°C. The produced formazan was eluted in DMSO and quantified by measuring at wavelength 
570nm by a spectrophotometer. (n = 2) 
 
4.3.2 Virus spread in the presence of double drugs 
The spread of HPAIV in the presence of combined MI-701 and oseltamivir was first 
examined. MDCK cells were infected with FPV at a low MOI and were incubated with 
10µM, 25µM and 50µM MI-701, 0.01µM, 0.1µM and 0.5µM oseltamivir alone or in 
combination. Infected cells were immunostained using anti-FPV antibody at 48h p.i.. 
Single drug treatment with MI-701 at the concentration ≥ 25µM or oseltamivir at the 
concentration of 0.5µM strongly suppressed virus propagation, whereas 10µM MI-701 
and oseltamivir ≤ 0.1µM were not sufficient to inhibit virus replication at 48h p.i. (Fig. 
4.10). Combination treatment with 10µM MI-701 and 0.1µM oseltamivir remarkably 
suppressed the comet-like foci of virus spread in MDCK cells, and combination of 
50µM MI-701 and 0.5µM oseltamivir completely blocked the virus spread in MDCK 
cells. Therefore, it was demonstrated that combination treatment of furin inhibitor MI-
701 and oseltamivir could achieved more efficient inhibitory efficacy than treatment 
with a single drug (monotreatment).  
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Fig. 4.10: Virus spread in the presence of MI-701 and oseltamivir. MDCK cells were infected with 
FPV at an MOI of 0.001. Infected cells were treated with inhibitor MI-701 at 10, 25 or 50µM, and 
oseltamivir at the concentration of 0.01, 0.1 or 0.5µM respectively, or in combination. As controls, both 
uninfected cells and infected cells were incubated in pure medium in the absence of inhibitor. At 24h p.i. 
cells were fixed with 4% PFA and infected cells were immunostained using anti-FPV antibody and HRP-
conjugated anti-rabbit secondary antibody. Microscopic images of infected cells are shown in Fig. S3 in 
supplementary. 
 
4.3.3 Virus replication in the presence of double drugs  
In order to better evaluate the inhibitory efficacy of combined inhibitors for treatment 
the HPAIV infection, the replication of HPAIV in the presence of MI-701 and oseltamivir 
was examined. MDCK cells were infected with FPV or KAN-1 virus at an MOI of 0.0001 
and treated with inhibitor MI-701 and oseltamivir in combination (Fig. 4.11). Treatment 
with 10µM MI-701 and 0.1µM oseltamivir in conjunction completely blocked the FPV 
virus propagation at 18h p.i. and thereby caused about 10000-fold virus titer reduction 
at 24h p.i.. When the concentration of oseltamivir was increased to 0.5µM, no virus 
was detected at 24h p.i. and resulted in ten thousand-fold virus titer reduction at 48h 
p.i. (Fig. 4.11A). In comparison with the data of FPV, 10µM MI-701 in combination with 
different concentrations of oseltamivir, 0.01µM, 0.1µM and 0.5µM, did not completely 
inhibit replication of KAN-1 virus at 18h p.i.. Virus replication was totally blocked at 48h 
p.i. in the presence of 50µM MI-701 and 0.5µM oseltamivir (Fig. 4.11B, left). All the 
data above demonstrated that the double combination with MI-701 and oseltamivir 
remarkably enhanced antiviral activity against the HPAIV infection in comparison with 
monotreatment with either MI-701 or oseltamivir. 
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Fig. 4.11: HPAIV multicycle replication in the presence of double drugs. MDCK cells were infected 
with FPV (A) of KAN-1 (B) virus at an MOI of 0.0001. Virus dilution was removed after 1h. Infected cells 
were washed with PBSdef and treated with MI-701 (MI) at the concentration of 10µM, 25µM or 50µM in 
combination with 0.01µM, 0.1µM or 0.5µM oseltamivir (Os). As a control, infected cells were incubated 
in DMEM medium (w/o FCS) without inhibitors. At 18h, 24h, 48h, 72h and 96h p.i., virus-containing 
supernatants were collected for virus titer determination using plaque assay. (n ≥ 3) 
 
4.3.4 Virus replication in the presence of triple drugs 
Subsequently, the MI-701 was combined with oseltamivir and ribavirin for treatment 
the infection of HPAIV. MDCK cells were infected with FPV or KAN-1 virus at a low 
MOI and treated with MI-701, oseltamivir and ribavirin in combination at indicated 
concentrations. In comparison with double treatment, virus titer in triple drugs-treated 
cells was further reduced. Some combinations completely inhibited virus release by 
96h (Fig. 4.12). Presence of MI-701, oseltamivir and 10µM ribavirin maximally inhibited 
the release of FPV by 48h, whereas when cells treated with 50µM MI-701, 0.5µM 
oseltamivir and 25µM ribavirin, the release of FPV was blocked completely by 96h (Fig. 
4.12A). As for the KAN-1 virus, triple combination with MI-701, oseltamivir and 10µM 
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ribavirin also maximally blocked virus production by 48h (Fig. 4.12B), and when the 
concentration of ribavirin was increased from 10µM to 25µM, their inhibitory efficacy 
was significantly enhanced. Virus yield was completely blocked by 96h in cells treated 
with 10µM MI-701, 0.5µM oseltamivir and 25µM ribavirin or treated with MI-701 ≥ 25µM, 
oseltamivir > 0.01µM and 25µM ribavirin.  
In addition, the viability of infected cells with or without treatment was examined at 96h 
p.i. by NR assay (Fig. 4.13). Infected cells without inhibitor treatment lost almost all 
viability at 96h p.i., whereas cells treated 50µM MI-701, 0.5µM oseltamivir and 25µM 
ribavirin, which completely blocked the virus yield at 96h p.i., still preserved 
approximately 70% viability. The loss of 30% viability was likely due to the virus 
infection, because combination treatment of uninfected cells did not result in any loss 
of viability (Fig. 4.9).  
Altogether, it is demonstrated that infected cells benefited from the triple combination 
treatment. The inhibitory efficacy of triple combination treatment with MI-701, 
oseltamivir and ribavirin is greater than that of the double combination treatment or 
monotreatment. Importantly, triple combinations, which are capable to completely 
block the virus release by 96h, did not induce any toxic effects to the treated cells.  
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Fig. 4.12A: Multicycle replication of HPAIV subtype H7N1 in the presence of triple drugs. MDCK cells were infected with FPV at an MOI of 0.0001. After 
virus adsorption for 1h, unbound viruses were quickly washed off with PBSdef and cells were treated with MI-701 (MI) (10µM, 25µM or 50µM), oseltamivir (Os) 
(0.01µM, 0.1µM or 0.5µM) and ribavirin (10µM or 25µM). Control cells were infected and incubated in medium in the absence of inhibitor. At time points, 18h, 
24h, 48h, 72h and 96h p.i., virus-containing supernatants were collected and the virus titer was determined by plaque assay. (n ≥ 3). * Virus yield was completely 
blocked in cells treated with 50µM MI-701, 0.1µM/0.5µM oseltamivir and 25µM ribavirin and was shown as ▲ in indicated colour. 
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Fig. 4.12B: Multicycle replication of HPAIV subtype H5N1 in the presence of triple drugs . MDCK cells were infected with KAN-1 virus at an MOI of 0.0001. 
After virus adsorption for 1h, unbound viruses were quickly washed off with PBSdef and cells were treated with MI-701 (MI) (10µM, 25µM or 50µM), oseltamivir 
(Os) (0.01µM, 0.1µM or 0.5µM) and ribavirin (10µM or 25µM). Control cells were infected and incubated in medium in the absence of inhibitor. At time points, 
18h, 24h, 48h, 72h and 96h p.i., virus-containing supernatants were collected and the virus titer was determined by plaque assay (n ≥ 3). * Virus yield was 
completely blocked in cells treated with 25µM/50µM MI-701, 0.1µM/0.5µM oseltamivir and 25µM ribavirin and was shown as ▲ in indicated colour. 
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Fig. 4.13: Viability of inhibitor treated infected cells at 96h p.i.. The viability of treated cells at 96h 
p.i. was determined by neutral red assay. MDCK cells were infected with FPV or KAN-1 virus at MOI of 
0.0001. 1h after virus adsorption, infected cells were treated with triple drugs, MI-701 (MI), oseltamivir 
(Os) and ribavirin (rib) at indicated concentrations. MI/Os/rib: 25/0.01/25µM, 25/0.1/25µM, 25/0.5/25µM, 
50/0.01/25µM, 50/0.1/25µM and 50/0.5/25µM. As controls, infected cells and uninfected cells (mock) 
were incubated in DMEM medium (w/o FCS) in the absence of inhibitors. At 96h p.i. cells were stained 
with neutral red and quantified by measuring at wavelength 562nm by a spectrophotometer. For 
quantification, the viability of infected cells was normalized against that of the control mock cells, which 
was set to 100%. (n = 3) 
 
Furthermore, the vesicular stomatitis virus (VSV) was used to examine the possible 
toxic effects of combined furin inhibitor MI-701 and oseltamivir on virus itself. Ribavirin 
was not tested in this experiment, presence of it can inhibit the growth of VSV (Toltzis 
& Huang 1986), and is therefore not suitable for this control test.  
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Vero E6 cells were infected with VSV at a low MOI 0.0001. Infected cells were then 
incubated in DMEM medium (w/o FCS) containing MI-701 and oseltamivir alone or in 
combination. Since VSV does not contain neuraminidase and its replication is not 
dependent on efficient cleavage of its glycoprotein, presence of furin inhibitor and 
neuraminidase inhibitor should not have influences on the replication of VSV in cell 
cultures. As expected, replication of VSV was not affected in the presence of either MI-
701, oseltamivir alone or in combination, indicating that the MI-701 and oseltamivir in 
combination did not induce any toxic effects to the cells (Fig. 4.14).   
 
 
Fig. 4.14: Vesicular stomatitis virus control infection. Vero E6 cells were infected with vesicular 
stomatitis virus (VSV) at an MOI of 0.0001. After virus adsorption for 1h, infected cells were treated with 
50µM MI-701 (MI), 0.5µM oseltamivir (Os) alone or in combination. Control cells were infected with VSV 
without treatment. At different time points, 6h, 24h and 48h p.i. virus-containing supernatants were 
collected and the virus titer was determined by plaque assay. (n = 2) 
 
4.3.5 Determination of the 50 percentage effective concentration of MI-701, 
oseltamivir and ribavirin as single drugs or in combination 
The 50% effective concentration (EC50) is defined as the concentration of a drug that 
can inhibit virus replication up to 50% and is an important pharmacological parameter 
for drug development. MDCK cells in 96-well plates were infected with FPV at an MOI 
of 0.0001. Infected cells were then treated with serially diluted MI-701, oseltamivir and 
ribavirin alone or in combinations. The EC50 of each drug was determined by 
measuring the extent of virus-induced CPE in MDCK cells at 48h p.i. using neutral red 
assay (NR assay) (Table 4.1).  
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Table 4.1: Reduction of EC50 for MI-701 as single agent or in double and triple combinations1. 
 
1 The NR data was plotted as percent inhibition versus compound concentration and shown in Fig. S4 
   in supplementary. 
2 A confidence interval can tell how precisely the value is determined. 95% confidence interval means  
   a range of values that is 95% certain contains the true value. 
3 The reduction fold of EC50 is calculated by dividing the EC50 of MI-701 by the EC50 of combined 
   drugs. 
 
As shown in Table 4.1, the EC50 for MI-701 and ribavirin were in micromolar range, 
whereas oseltamivir was in nanomolar range. The potency of MI-701 was enhanced 
when it was combined with oseltamivir. The EC50 for MI-701 was 2.1-fold reduced in 
the presence of 0.01µM oseltamivir and 2800-fold reduced when the concentration of 
oseltamivir was increased from 0.01µM to 0.5µM. Moreover, the EC50 for MI-701 was 
further reduced in triple combination with oseltamivir and ribavirin. The highest 
reduction, 14000-fold reduction, was seen in the presence of 0.5µM oseltamivir and 
1µM ribavirin compared to that of the MI-701 used as a single agent. Therefore, the 
antiviral activity of MI-701 was greater in triple combination than in double combination 
or as a single agent. This observation indicated that lower dose of each drug were 
required in combination to achieve the same inhibitory effect caused by single-drug 
treatment.  
4.3.6 Synergy analysis 
When two or more drugs are used in combination to inhibit virus replication, they can 
produce drug-drug interactions defined as “synergistic,” “additive,” or “antagonistic” 
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when their combined effect exceeds, equals, or less than that of the sum of the effects 
of the individual drugs, respectively (Govorkova & Webster, 2010). 
 
 
 
Fig. 4.15: Synergistic inhibition of MI-701 in double combination and triple combination against 
FPV. MDCK cells in 96-well plates were infected with FPV at an MOI of 0.0001 and then treated with 
serially diluted MI-701 and oseltamivir in combination (A) or plus 1µM or 10 µM ribavirin in triple 
combination (B). 48h after infection the extent of virus-induced CPE in each well was determined by 
neutral red (NR) staining. Grey areas indicated the interaction was additive, blue areas indicated the 
synergistic interaction and red areas indicated the antagonistic interaction. The intensity of the color 
corresponded to the percent inhibition above (synergistic) or below (antagonistic) the expected level. 
Data are presented as the mean values of 3 replicates with 95% confidence intervals. NR data are 
shown in Fig. S6 in supplementary. 
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To access the possible interaction between MI-701, oseltamivir and ribavirin in 
combinations, MDCK cells were seeded in 96-well plates and treated with serially 
diluted MI-701 in combination with oseltamivir or together with 1µM or 10µM ribavirin. 
At 48h p.i. the CPE of cells were measured by NR staining (experimental design in 96-
well plate see Fig. S6 in supplementary). The theoretical calculated additive inhibition 
is generated from the dose-dependent curve of single inhibitor using specific equations 
(for double combination: Z = X + Y (1-X), X, Y represent that inhibition produced by 
inhibitor X or Y, respectively, Z refers to the total inhibition produced by inhibitor X and 
Y in combination; the equation for calculating the total inhibition produced by triple 
drugs has not been published) (Prichard & Shipman, 1990). The calculated additive 
inhibition is then subtracted from the experimentally determined inhibition to reveal 
different drug-drug interactions (all the calculations were generated after entering the 
NR data manually in the Excel worksheet of the MacSynergy III program). The data 
were presented as contour plots, in which the experimental inhibition effect was equal 
to, greater or less than the theoretical calculated additive inhibition, and are shown in 
grey, blue and red, respectively. As shown in Fig. 4.15A the MI-701 and oseltamivir in 
double combination was largely additive; synergy was observed within the 
concentration range from about 0.39µM to 1.5µM for MI-701 and 0.2µM to 0.4µM for 
oseltamivir. No antagonism was found. Triple-combination of MI-701, oseltamivir and 
ribavirin was synergistic against the replication of FPV across a wide range of 
concentrations, and the synergy area was expanded along with the increasing 
concentration of ribavirin from 1µM to 10µM. Triple combination with ribavirin at the 
concentration 10µM reached the limits of NR assay, thus the EC50 of MI-701 in triple 
combination with oseltamivir and 25µM ribavirin was not determined. 
4.4 Effects of treatment initiation on antiviral activity  
The antiviral efficiency of a drug is related to the life cycle of the treated viruses and 
the time of drug-application. MDCK cells were infected with FPV at a low MOI. 
Inhibitors were added to the cells at given time points. Cells were fixed at 48h p.i. and 
immunostained using anti-FPV antiserum (Fig. 4.16A). Under the low-MOI conditions 
a larger number of cells were not initially infected with the FPV. Without treatment 
almost all the cells were infected with FPV at 48h p.i. due to the secondary infection. 
Triple treatment with MI-701, oseltamivir and ribavirin immediately after virus 
adsorption efficiently protected the neighbouring uninfected cells. The FPV usually 
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starts to release progeny viruses at 6h to 8h p.i., and treatment initiated at 6h p.i. was 
still capable to efficiently suppressed virus spread. However, treatment started at 14h 
p.i. or later no longer prevented infection (Fig. 4.16B).   
 
 
 
Fig. 4.16: Time of inhibitor addition. (A) Schematic image of experiment build up. MDCK cells were 
infected with FPV at an MOI of 0.001. Infected cells were treated immediately or 6h, 14h, 20h, 30h after 
infection with 50µM MI-701(MI), 25µM ribavirin (rib) and together with oseltamivir (Os) at different 
concentration, 0.01, 0.1 and 0.5µM, respectively. Control cells were infected with FPV without inhibitor 
treatment. Mock cells were not infected with FPV. At 48h p.i. cells were fixed with 4% PFA and then 
infected cells were immunostained against anti-FPV antibody and HRP-conjugated anti-rabbit 
secondary antibody (B). Virus-containing supernatants of each well were collected and titrated by plaque 
assay (C).  
4. Results 
80 
 
Released viruses were quantified by plaque assay (Fig. 4.16C). Complete inhibition 
was observed when treatment was initiated immediately after infection (0h p.i.). 
Treatment at 6h p.i. led to up to one million reduction of virus yield when compared 
with untreated cells. Although a larger amount of virions were released into the 
supernatants, initiation of triple combination treatment at this time point resulted in up 
to 1000-fold virus titer reduction. Initiation of triple combination treatment after 30h p.i. 
was insufficient to inhibit virus replication.  
Taken together this experiment showed that triple treatment with MI-701, oseltamivir 
and ribavirin exerted their antiviral effects during the early stage of virus replication 
cycle, suggesting that triple treatment should be conducted as early as possible but 
not later than 2 days after infection to obtain an optimal antiviral activity. 
4.5 Development of drug-resistant FPV 
Challenger of the current anti-influenza therapy is the worldwide rapid emergence and 
circulation of drug-resistant viruses. The potent furin inhibitor MI-701 was proven to be 
an efficient anti-influenza agent, either used for a mono-treatment or for combination 
treatment with oseltamivir and ribavirin. However, the potential of furin inhibitor MI-701 
to develop resistant influenza is unclear. Previous studies showed that combinatorial 
therapy using different virus-targeting antivirals reduced the emergence of drug-
resistant influenza variants (Ilyushina et al., 2006). In this chapter FPV was used to 
examine whether treatment with oseltamivir and furin inhibitor MI-701 alone would lead 
to occurrence of resistant FPV mutants and whether combination treatment with both 
inhibitors would suppress the development of drug-resistant FPV mutants.  
4.5.1 Propagation of FPV in the presence of MI-701  
To investigate the possible development of MI-701-resistant viruses, FPV was serially 
passaged in MDCK cells under an increasing concentration of MI-701 for eight times. 
The concentration of MI-701 was doubling in each subsequent passage. Virus 
susceptibility to MI-701 was controlled by plaque reduction assay. By the seventh 
passage there was still no significant susceptibility changes detected between viruses 
that propagated in medium in the absence of inhibitor MI-701 and viruses, which were 
passaged under an increasing concentration of inhibitor MI-701 (Fig. 4.17).  
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Fig. 4.17: Susceptibility of passaged FPV to furin inhibitor MI-701. Plaque reduction assay was 
used to monitor the susceptibility of FPV to furin inhibitor MI-701. MDCK cells were infected with 50 PFU 
of FPV viruses that were passaged in the infection medium in the absence of inhibitors (FPV_control) 
or in the presence of MI-701 (FPV_MI-701). After incubation at 37°C for 1h, the virus inoculum was 
removed and fresh 1.2% avicel overlay medium containing 2% FCS and desired concentration of MI-
701 was added to the cells. 48h after incubation overlay medium was removed and cells were fixed by 
4% PFA. Infected cells were immunostained against anti-FPV antibody and HRP-conjugated anti-rabbit 
secondary antibody.  
 
Therefore, it was concluded that propagation of FPV under the pressure of furin 
inhibitor MI-701 did not resulted in development of drug-resistant viruses. This result 
was confirmed by sequence analysis. No mutations were found in either HA or NA 
protein of FPV_MI-701 viruses (Table 4.2). 
4.5.2 Propagation of FPV in the presence of oseltamivir  
FPV wild type, which is not resistant to oseltamivir, was passaged in MDCK cells under 
an increasing concentration of oseltamivir. Virus titer of each passaged FPV was 
determined by plaque assay. Every three to four passages, the susceptibility of 
passaged virus to oseltamivir was monitored by plaque reduction assay.  
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Fig. 4.18: Susceptibility of passaged FPV to oseltamivir. Plaque reduction assay was used to 
monitor the susceptibility of FPV to oseltamivir. MDCK cells were infected with 50 PFU of FPV, which 
was passaged in the absence of oseltamivir (FPV_control) or in the presence of oseltamivir 
(FPV_oseltamivir). After incubation at 37°C for 1h, virus inoculum was removed and fresh 1.2% avicel 
overlay medium containing 2% FCS and 0.01µM, 0.1µM, 1µM, 10µM and 100µM oseltamivir was added 
to the cells, respectively. 48h after incubation overlay medium was removed and cells were fixed by 4% 
PFA. Infected cells were immunostained against anti-FPV antibody and HRP-conjugated anti-rabbit 
secondary antibody.  
 
After four passages, the susceptibility of FPV_oseltamivir that was passaged in the 
presence of increasing concentration of oseltamivir, was slightly decreased in 
comparison with FPV that was passaged in medium in the absence of oseltamivir (Fig. 
4.18). FPV_oseltamivir formed more plaques in the presence of 0.1µM and 1µM 
oseltamivir than FPV control virus that was passaged in the absence of inhibitors. Many 
small plaques with a diameter less than 1mm were found in FPV_oseltamivir infected 
cells in the presence of 10µM and 100µM oseltamivir, but not in FPV_control virus-
infected cells. The FPV was further passaged under the concentration of oseltamivir 
and by the seventh passage the susceptibility of FPV_oseltamivir virus to oseltamivir 
was distinctly decreased. Bigger plaques were formed in the presence of 10µM and 
100µM oseltamivir, while no plaques were formed in cells infected with FPV control 
viruses in the presence of 10µM or 100µM oseltamivir. After sequence analysis of the 
NA gene of the FPV control virus and FPV_oseltamivir viruses from the fourth and 
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seventh passage, a histidine to tyrosine substitution mutation at amino acid 275 (in N1 
numbering) in NA was confirmed, The H275Y mutation was a well known oseltamivir-
resistant mutation, which has been found in many oseltamivir-resistant influenza A 
isolates, including pandemic 2009 H1N1 and human pathogenic H5N1 (de Jong et al., 
2005; van der Vries et al., 2010). The NA gene of FPV and FPV_oseltamivir virus from 
selected passages were also sequenced and results are showed in Table 4.2. The 
NAH275Y mutation first appeared in the third passage and was continually identified in 
subsequent passages. The H275Y mutation was the only mutation that the FPV 
developed under the pressure of oseltamivir. In repeated experiment a mixture of 
H275H and H275Y in NA were detected in the FPV_oseltaviri virus in the third passage 
(data not shown).   
4.5.3 Propagation of FPV in the presence of oseltamivir and furin inhibitor MI-
701  
FPV was passaged eight times in the presence of oseltamivir and MI-701. The 
concentration of oseltamivir was doubled in the subsequent passage, whereas the 
concentration of MI-701 was constant at 10µM, 25µM or 50µM. To determine the 
possible appearance of mutations, the NA and HA genes of viruses were fully 
sequenced from indicated passages (Fig. 4.19 and Table 4.2).  
 
Table 4.2: Sequence analysis of FPV variants in the presence of drugs in vitro 
 
a: only NA full gene was sequenced 
b and c: both NA and HA full genes were fully sequenced 
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By the fourth passage, another mutation was detected. An amino acid substitution at 
position 295, asparagines to serine (N295S), in NA was detected in FPV that was 
passaged in the presence of oseltamivir and 50µM MI-701. As for FPV that was 
passaged in the presence of oseltamivir and 25µM MI-701, the mutation H275Y in NA 
appeared in the eighth passage. This was five passages later than the mutations that 
occurred in FPV passaged in the presence of oseltamivir alone. A double mutation 
(I223M/P272H) with amino acid substitution at position 223, isoleucine to methionine 
(I223M), and proline to histidine at position 272, was detected in FPV that passaged in 
the presence of oseltamivir and 10µM MI-701 in the third passage.  
 
 
 
Fig. 4.19: Sequence analysis is represented in chromatogram. Four mutations, I223M, P272H, 
N295S and H275Y in NA are indicated using red box.  
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Fig. 4.20: Crystal structure of group-1 (N1) NA monomer in ribbons representation (A) and NA 
tetramer in surface representation (B). Catalytic residues in NA are shown in yellow, the framework 
residues in NA are shown in blue and the NA residues, I223, P272, H275 and N295 are shown in red. 
The H275 residue, which was located inside the active site, was not indicated in (B).  
PDB accession codes. The crystal structure is available from the RCSB PDB under accession codes 
2HTY for the avian influenza H5N1. (www.rcsb.org/pdb/explore/explore.do?structureld=2hty) 
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The four mutations on the virus, the four mutated residues, H275Y, I223M, P272H and 
N295S, together with critical residues in NA active site were projected onto the three-
dimensional structure of NA derived from avian H5N1 (Fig. 4.20). The active site of 
influenza virus NA contains nine conserved catalytic residues: R119, D152, R153, 
R225, E277, R293, R372, and Y407 that directly interact with the substrate and 11 
conserved framework residues: E120, R157, W179, S180, D/N199, I223, E228, H275, 
E278, N295, and E426 that support the catalytic residues. As shown in Fig. 4.20A, the 
three mutations at the positions 223, 275 and 295 were in the framework residues 
surrounding the catalytic residues, while the mutation at the position 272 was distal to 
the active site. Residues at the positions, 223, 295 and 272 were surface exposed, 
whereas the residue at position 275 was located inside of the active site, which could 
not be detected on the surface of NA. 
4.5.4 Virus susceptibility to oseltamivir in vitro 
An NA enzyme inhibition assay was used to characterize the susceptibilities of FPV 
variants to oseltamivir (Fig. 4.21).  
 
 
 
Fig. 4.21: NA enzyme inhibition assay of FPV mutants. The susceptibility of FPV variants to 
oseltamivir was determined by MUNANA-based enzyme inhibition assay. Viral dilution, which emits an 
equivalent RFU generated by 10μM 4-methyumbelliferone sodium salt (4-MUSS) was selected 
afterwards for NA enzyme inhibition assay. Viruses were incubated at 37°C for 30min with 4mM of 
oseltamivir and then 30min with fluorogenic MUNANA substrate at a final concentration of 200µM. The 
fluorescence of released 4-methylumbelliferone (4-MU) was measured with an Epoch microplate 
spectrophotometer. (n = 3) 
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The concentration of oseltamivir that was required to inhibit 50% (IC50) of NA enzymatic 
activity of FPV and FPV mutants was calculated and shown in Table 4.3. The 
oseltamivir IC50 of FPV was 5.57nM, 50.69nM for the FPV_NAI223M/P272H virus, 
112.11nM for the FPV_NAN295S virus and 784.23nM for the FPV_NAH275Y virus. The 
single mutation H275Y in NA remarkably reduced the susceptibility to oseltamivir. The 
IC50 of FPV_NAH275Y virus to oseltamivir was 140-fold increased, whereas the IC50 of 
virus with single mutation N295S in NA and double mutations I223M/P272H in NA to 
oseltamivir were moderately increased, approximately 20-fold and 9-fold, respectively. 
 
Table 4.3: Susceptibility of FPV mutants to oseltamivir. 
 
* Mean±SD was derived from two independent measurements.  
** The reduction fold in IC50 was calculated by dividing the IC50 of FPV mutant by the IC50 of FPV wild 
type. 
 
4.5.5 Biological characterization of FPV variants 
The effects of the NA mutations H275Y, N295S and I223M/P272H on the fitness of the 
viruses were determined by comparing their growth kinetics with those of FPV wild 
type viruses.   
4.5.5.1 Growth kinetics of FPV variants in cell cultures 
The growth kinetic of FPV variants in MDCK cells was examined to further analyze the 
impact of these NA mutations. As shown in Fig. 4.22, wild type FPV replicated 
efficiently in MDCK cells and rapidly reached approximately 105 PFU/ml at 14h p.i., 
whereas FPV_NAN295S and FPV_NAI223M/P272H produced approximately 1000-fold less 
virus particles. Virus titer was 10-fold reduced in FPV_NAH275Y-infected cells. 
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Fig. 4.22: Growth FPV wild type and FPV mutants in cell cultures. MDCK cells were infected with 
FPV wild type or FPV_NAH275Y, FPV_NAN295S, FPV_NAI223M/P272H viruses at an MOI of 0.0001, 
respectively. Infected cells were incubated in DMEM infection medium at 37°C. At indicated time points, 
14h, 24h, 48h and 72h p.i., virus-containing supernatants were collected and released viruses were 
titrated by plaque assay. (n=2) 
 
48h after infection, all variants reached a comparable titer (approximately 108 PFU/ml) 
to that of the wild type virus, except for the FPV_NAI223M/P272H virus, which produced 
100-fold less progeny viruses. 
4.5.5.2 Effect of furin inhibitor MI-701 on replication of FPV mutants 
Although the presence of MI-701 did not prevent the development of oseltamivir-
resistant mutations in FPV virus, no mutation related to the resistance to MI-701 was 
found. To investigate the effect of MI-701 on oseltamivir-sensitive and -resistant 
viruses, MDCK cells were infected with FPV wild type virus, FPV_NAH275Y, 
FPV_NAN295S or FPV_NAI223M/P272H virus at a low MOI, respectively and infected cells 
were treated with MI-701 at a concentration of 50µM (Fig. 4.23).  
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Fig. 4.23: Inhibitory efficacy of MI-701 on FPV mutants replication. MDCK cells were infected with 
FPV wild type virus (FPV) or FPV_NAH275Y, FPV_NAN295S or FPV_NAI223M/P272H viruses at an MOI of 
0.0001, respectively. Infected cells were treated with 50µM MI-701 or incubated in DMEM medium (w/o 
FCS) in the absence of inhibitor. At indicated time points, 18h, 24h, 48h and 72h p.i., virus-containing 
supernatants were collected and released viruses were titrated by plaque assay. 
 
As shown in Fig. 4.23, treatment with 50µM MI-701 significantly inhibited the replication 
of both FPV wild type virus and its mutant viruses FPV_NAH275Y, FPV_NAN295S, 
FPV_NAI223M/P272H at 18h p.i., which indicated that furin inhibitor MI-701 could be a 
potential drug against the infection of oseltamivir-resistant HPAIV.  
Above all, it was demonstrated that the presence of oseltamivir and 25µM furin inhibitor 
MI-701 suppressed the development of an oseltamivir-resistant mutation. In the 
presence of oseltamivir and furin inhibitor MI-701, a mutation N295S and a double 
mutation I223M/P272H were detected in NA in the early virus passages. However, 
they exhibited mild reduction of susceptibility to oseltamivir and reduced or 
compromised replication ability in MDCK cells. 
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5 Discussion 
The targets of antiviral drugs are either virus-encoded proteins or host factors that are 
essential for virus replication. It is well known that proteolytic processing of HA is an 
absolute requirement for influenza A virus infection. The responsible HA activating 
proteases were elucidated during the last decades. These proteases are normally 
provided by the host organism and occasionally by individual co-infecting 
microorganisms (Böttcher-Fiebertshäuser et al., 2013). The application of specific 
protease inhibitors seems to be possible unless inactivation of the protease causes 
severe adverse effects in organisms.  
5.1 Furin as a drug target for prevention of HPAIV infection 
Furin is a well-studied key protease which converts numerous biologically inactive 
protein precursor molecules into their active forms. It cleaves HA0 of highly pathogenic 
avian influenza virus (HPAIV) at a defined multibasic amino acid motif. The cleavage 
mainly occurs in the TGN before the virus particles are assembled at the plasma 
membrane (Fig. 1.8). Since furin is ubiquitously expressed in nearly all cells and 
tissues (Seidah et al., 1994), it supports the spread of HPAIV infections from 
endothelial cells of the respiratory tract to practical all tissues and organs under natural 
conditions. The spread of infection primarily occurs along endothelial cells of the blood 
vessel system, and thus causes systemic infections in the organisms with severe 
outcomes (Feldmann et al., 2000; Liem et al., 2009; Puthavathana et al., 2005). Due 
to furin’s indispensable role during the infection of HPAIV, the efficient inhibition of furin 
at an early stage is thought to be a promising treatment for HPAIV infections. However, 
application of furin inhibitors will only be successful when other proteases unaffected 
by furin inhibitor can compensate for the lack of furin. Additionally, these compensatory 
proteases must not activate the HA of HPAIV (Garten & Klenk, 2008).  
Early study showed that furin knockout mice die at an early embryonic stage because 
of severe defects, which indicates the physiological importance of furin during 
embryonic development. In contrast to the embryonic lethality of furin deficient mice, 
no obvious adverse effects were observed in adult transgenic mice with an interferon 
inducible knockout system for furin (Roebroek et al., 1998, 2004). A nearly complete 
elimination of furin in the liver resulted in no overt deviations from normal morphology. 
The natural substrates of furin, such as the proproteins of insulin receptor, albumin, α5-
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integrin, lipoprotein receptor-related protein, vitronectin, and of α1-
microglobulin/bikunin, were correctly proteolytically processed in the absence of furin. 
This indicates that an obviously redundancy for proteolytic processing of physiological 
proproteins provided by other members of the PCs family exist in the liver (Roebroek 
et al., 2004). Altogether, the absence of any severe phenotype of furin deficient adult 
mice raises the possibility that the treatment of HPAIV infections with furin inhibitors 
will be successful. Additional support for a possible application of furin inhibitors as 
potential drugs in adult organisms comes from furin knockout cell lines, like furin-
deficient LoVo and CHO (FD11) cells, which are fully viable despite furin’s inability to 
cleave any substrate.  
The concept of furin blockage by specific inhibitors as an antiviral drug therapy has 
been suggested by Garten and co-workers since 1992. Initially the instable furin 
inhibitor dec-RVKR-cmk was used (Hallenberger et al., 1992; Stieneke-Gröber et al., 
1992; Garten et al., 1994), although now it has been replaced by much more stable 
and efficient compounds, such as MI-701 (Becker et al., 2010; 1012).  
5.2 Development and evaluation of furin inhibitors  
The known furin inhibitors can be categorized into following groups: (I) peptide 
derivatives compounds including, such as peptidomimetics containing the furin 
recognition motif, (II) small synthetic non-peptidic compounds, and (III) 
macromolecular inhibitors, including naturally occurring proteins and genetically 
modified proteins (see 1.4.3.1.1 and Table 5.1). 
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Table 5.1: Reported furin inhibitors 
 
[1] Dahlen et al., 1998; [2] Jean et al., 1999; [3] Lu et al., 1993; [4] Bontemps et al., 2007; [5] Liu et al., 
2004; [6] Basak et al., 2010; [7] Basak & Lazure, 2003; [8] Carmeron et al., 2000; [9] Basak et al., 1997; 
[10] Basak, 2005; [11] Kacprzak et al., 2004; [12] Hallenberger et al., 1992; [13] Villemure et al., 2003; 
[14] Angliker, 1995; [15] Basak et al., 1999; [16] Podsiadlo et al., 2004; [17] Jiao et al., 2006. 
* Macromolecules contain naturally occurring and genetically modified proteins. ** A15R, T17K and 
L18R are amino acid substitution mutations. *** IC50 value. 1 Histatin 3. 2 Histatin 5.  
 
The first small peptidomimetic inhibitors were developed on the basis of the furin 
recognition motif in 1990s, e. g. decanoylated tetrapeptidyl-chloromethyl ketones like 
the commercially available dec-RVKR-cmk, which covalently binds to the catalytic site 
of furin (Garten et al., 1994; Stieneke-Gröber et al., 1992; Hallenberger et al., 1992; 
Henrich et al., 2003). Over the last five years, such peptidomimetic furin inhibitors have 
been further developed and optimized. In this thesis, a series of 4-
amidinobenzylamide-based inhibitors were screened for an enhancement of inhibitory 
efficacy. Most compounds were well tolerated by MDCK cells up to a concentration of 
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50µM. In particular, the compound MI-701 was non-toxic to the cells even at higher 
concentrations (up to 400µM) (Fig. 4.2). However, the compounds MI-259, MI-232, MI-
233 and MI-283 (structures are shown in Table S3 in supplementary) containing longer 
saturated or unsaturated P5 acyl residues with more than 11 carbon atoms showed 
considerable reduction of cell viability and thus they were not further investigated (Fig. 
4.1). Cleavage of HA was inhibited to different extents by the listed furin inhibitors (Fig. 
4.4). An optimal suppression of the spread and propagation of H7N1 and H5N1 viruses 
was achieved by compound MI-701. This inhibitor proved to be stable in cultured 
MDCK cells for several days (Fig. 4.3). Approximately 50% of MI-701 could be 
recovered from cell supernatants after 96h. On one hand, this observation underlines 
the stability of this compound. On the other hand, this fact explains the difficulties with 
the internalization of MI-701 into host cells. Inhibition of the intracellular activation of 
HA of HPAIV required a concentration of MI-701 in the micromolar range, whereas the 
inhibition of activation of the PA of Anthrax toxin on the cell surface required a much 
lower concentration of MI-701 in the nanomolar range. Hence, furin inhibitors, which 
are able to efficiently reach the lumina of the compartments of the intracellular 
secrectory pathway, may have an enhanced inhibitory efficacy against HPAIV 
infections. 
The following modifications were made to further improve the potency of the furin 
inhibitor MI-701: (i) N-terminal attachment of various cell penetrating peptides (CPPs), 
(ii) coupling of additional of D-arginine residues to the P4 arginine, (iii) replacement of 
valine at position P3 by tert-leucine and (iv) replacement of the P1 position 4-
amidinobenzylamide group in inhibitor MI-1148 by agmatine or noragmatine 
(structures and results are shown in Table S4 and Fig. S5 in supplementary).  
Some of the newly designed compounds such as MI-1148, the P3 Tle-analogue of the 
Val containing inhibitor MI-701, possesses a similar inhibitory potency as MI-701. 
Modifications the P5 or P1 group of MI-1148 did not enhance the antiviral activity. The 
attachment of CPPs facilitated the delivery of a wide variety of cargoes such as 
proteins, peptides, oligonucleotides, drugs, liposomes and micelles (Järver & Langel, 
2006; Madani et al., 2011), but our data and data by other researchers showed that 
the CPP transportan and penetratin induced toxicity in the cells (Saar et al., 2005). 
Several polyarginine-containing peptides proved to be potent furin inhibitors, such as 
the arginine-rich peptides modelled from the extended HA cleavage motif of H5N1 
influenza virus with a Ki value of 23nM (Shiryaev et al., 2007) and the nona-D-arginine 
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amide (D9R) with a Ki value of 1.3nM (Kacprzak et al., 2004). In this work, attachment 
of one or four D-arginine residues to the N-terminal P4 arginine (MI-1184 and MI-1187) 
enhanced the antiviral activity against HPAIV infection.  
Pharmacokinetic studies of optimized furin inhibitors still remain uncompleted. 
Adsorption and internalisation of MI-701 into various cells, its distribution in tissues, 
organs and in the whole organism, and its metabolism, degradation and elimination 
are of interest. Furthermore, different routes of MI-701 administration must also be 
examined.  
5.3 Binding of furin inhibitors  
The binding mode of 4-amidinobenzylamide based furin inhibitors to the active cleft of 
furin was initially modelled to better understand their interaction (Fig. 5.1) (Becker et 
al., 2010). Moreover, very recently the experimental crystal structures of inhibitors MI-
227 and MI-0052 in complex with human furin have been disclosed (Dahms et al., 
2014). The P1 amidinobenzylamide (Amba) group, which mimics the arginine side 
chain, deeply inserts into the S1 pocket of furin forming tight hydrogen bonds with the 
carbonyl oxygen atoms of P256 and A292 and an electrostatic interaction with D306. 
The P2 arginine side chain electrostatically interacts with D154 at the furin S2 pocket 
and forms additional interactions with N192 and D228. The backbone P3 valine binds 
to G255. The arginine side chain at P4 is stabilized by charged-assisted hydrogen 
bonds to E236, D264, Y308 and the carbonyl oxygen of G265. The N-terminal 
positively charged guanidinomethyl group attached in meta position to the P5 
phenylacetyl group of inhibitor MI-0052 forms an electrostatic interaction with E236, a 
water mediated hydrogen bond to D233, and an additional hydrogen bond to the 
carbonyl of V231 (Fig. 5.1B) (Dahms et al., 2014). 
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Fig. 5.1: Binding mode of synthetic inhibitors in the active site of human furin. (A) Stereoview of 
the complex between human furin presented with its solvent-exposed surface and inhibitor MI-227 
(phenylacetyl-Arg-Val-Arg-4-amidinobenzylamide, abbreviated: Phac-RVR-Amba), whereby the 
inhibitor is shown with grey carbon atoms (nitrogen and oxygen atoms are shown in blue and red, 
respectively). The surface of furin is coloured according to the electrostatic surface potential of the 
catalytic domain. (B) Binding of inhibitor MI-0052, showing important hydrogen bonds. Compound MI-
0052 (3-guanidinomethyl-phenylacetyl-Arg-Val-Arg-4-amidinobenzylamide, abbreviated: 3-Guame-
Phac-RVR-Amba) is a close analogue of the P5 para-substituted furin inhibitor MI-701 (4-Guame-Phac-
RVR-Amba), containing the N-terminal P5-guanidinomethyl group in meta position of the phenylacetyl 
residue. The backbone of furin is given as a cartoon representation. The carbon atoms of important furin 
residues involved in inhibitor binding are shown in grey. Figure (A) is taken from Dahms et al., 2014. 
Figure (B) was kindly provided by Kornelia Hardes, Institute of Pharmaceutical Chemistry, Philipps 
University Marburg. The structure of MI-227 and MI-0052 are shown in Table S3 in supplementary. 
 
5.4 Combinatorial drug treatment  
In the areas of disease prevention and treatment, the use of existing drugs in 
combination is an important complement to monotherapy. Combination therapy has 
been long used for the treatment of cancer as well as diseases caused by infectious 
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pathogens. Streptomycin was combined with different drugs and antibiotics, including 
isoniazid and rifamycins to improve the therapeutic effectiveness for the treatment of 
Mycobacterium tuberculosis (Daniel, 2006). A combination of interferon plus ribavirin 
is currently recommended for treatment of patients with chronic hepatitis C (Hauser et 
al., 2014). The highly active anti-retroviral therapy (HAART) used for treatment of 
human immunodeficiency virus type 1 (HIV-1) is the most successful example of a 
combination therapy, and has changed HIV infection from an incurable disease to a 
chronic one (Ascierto & Marincola, 2011). 
Combination therapy against influenza viruses has also been intensively studied. Early 
studies showed that combination of ribavirin with M2 ion channel inhibitors rimantadine 
or amantadine resulted in additive to synergistic antiviral effects on the influenza A 
viruses, including the subtypes H1N1, H3N2, H7N7 and H5N1 (Galegov et al., 1977; 
Hayden et al., 1980; 1984). Combination of the neuraminidase inhibitors zanamivir or 
oseltamivir with M2 ion channel inhibitors admantanes resulted in enhanced 
therapeutic effects against different influenza A viruses subtypes, inclusively the 
pandemic 2009 H1N1 influenza virus (Madren et al., 1995; Smee et al., 2009; 
Govorkova et al., 2004). Triple combination treatment with oseltamivir, amantadine and 
ribavirin was proven to be highly synergistic against multiple influenza viruses, 
including human seasonal influenza H1N1, H3N2 viruses and the avian influenza virus 
H5N1 (Nguyen et al., 2009). The inhibitory efficacy of this triple combination therapy 
was evaluated in vitro and in vivo against the infection of amantadine-, rimantadine- 
and oseltamivir-resistant influenza viruses H1N1 (Nguyen et al., 2012, 2010). 
Subsequent pilot study in patients showed that this triple combinatorial medication had 
comparable pharmacokinetics as monotherapy and could be administered safely in 
immunocompromised patients (Seo et al., 2013).  
The recent discovery of drugs with novel targets enhances the possibilities of influenza 
medications, including zoonotic influenza caused by HPAIV. Several novel anti-
influenza compounds are in various phases of clinical development. One of these, 
peramivir is an intravenously administered neuraminidase inhibitor. A combination of 
the new neuraminidase inhibitor peramivir with ribavirin reduced H1N1 virus infection 
in cell cultures and in mice (Smee et al., 2002). Favipiravir (T-705) has a mechanism 
of action that is not fully understood, but it is suggested that it targets influenza virus 
RNA-dependent RNA polymerase. The combination of favipiravir, with peramivir or 
oseltamivir, improved the survival of influenza A H1N1 infected mice and induced 
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additive effects against the pandemic 2009 H1N1 influenza A virus in mice (Smee et 
al., 2010; Tarbet et al., 2012, 2014). Another novel combination therapy is based on 
the MEK inhibitor, which is a host Ras-dependent Raf/MEK/ERK mitogen-activated 
protein (MAP) kinase signaling pathway inhibitor. This host kinase cascade is involved 
in influenza virus replication. The combination of the MEK inhibitor with oseltamivir led 
to a synergistic effect against pandemic 2009 H1N1 influenza A virus (Haasbach et al., 
2013). In addition, a combination of the host protease inhibitor BAPA and oseltamivir 
efficiently exhibited inhibitory potency against TMPRSS2-activated influenza A virus 
H1N1 and influenza B virus replication in airway epithelial cells (Böttcher-
Friebertshäuser et al., 2012). 
However, to date, few studies have evaluated the therapeutic effects of combination 
therapy on HPAIV infection. The work of Ilyushina et al. showed that oseltamivir-
ribavirin combination therapy provided a survival advantage for mice infected with 
HPAIV H5N1 (Ilyushina et al., 2007). The work of An et al. showed that the triple 
combination of neuraminidase inhibitor with two immunomodulatory inhibitors statins 
and fibrates exhibited synergistic effects against the HPAIV H5N1 infection in mice (An 
et al., 2011).  
This work showed that treatment with MI-701 and oseltamivir in combination resulted 
in significant virus titer reduction at 72h p.i. and some triple combinations of MI-701, 
oseltamivir and ribavirin completely blocked HPAIV KAN-1 virus yield at 72h p.i.. In 
contrast, the inhibitory efficacy of single drug treatment was no more observed at 72h 
p.i. (Fig. 5.2). Synergy analysis indicated that the combination of MI-701 and 
oseltamivir was largely additive against the HPAIV FPV, whereas synergy was 
observed in almost all tested concentrations of oseltamivir and MI-701 when they were 
combined with 10µM ribavirin (Fig. 4.15). This indicates that the antiviral activity of 
each drug in triple combination was increased compared to that in double combination 
or as a single drug. Importantly, no antagonism was observed for any combinations 
that were examined in this work, suggesting that combination treatment with MI-701 
and oseltamivir or together with ribavirin is unlikely to lead to reduced efficacy 
compared to single drug treatment. Although the synergy seen in cell culture would be 
different from that derived in mice experiments, these results should be helpful by 
suggesting the concentrations of each drug that maybe needed for successful 
combination treatment in mice. 
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Fig. 5.2: Reduction of KAN-1 virus yield at 72h p.i. after inhibitor treatment. This figure is based on 
the data of figure 4.11B and figure 4.12B. Virus titer at 72h p.i. in cells treated with 50µM MI-701, 0.5µM 
oseltamivir, 25µM ribavirin alone or with 50µM MI-701 and 0.5µM oseltamivir (MI/Os), or with 50µM MI-
701, 0.5µM oseltamivir and 25µM ribavirin in triple combination (MI/Os/Rib) were selected and 
compared to the virus titer in untreated infected cells.  
 
An important factor for a successful treatment of an acute infectious disease is the 
starting point of medication. The work of Smee et al. showed that almost the same 
concentration of peramivir, oseltamivir or ribavirin was needed to inhibit influenza A 
H3N2 induced CPE when treatment was started at 0h to 12h p.i., whereas a higher 
concentration of each drug was required to achieve 50% inhibitory effect when 
treatment started at 24h p.i. or 24h before infection (Smee et al., 2001). The work of 
Furuta et al. showed that favipiravir did not suppress virus yield when it was added 1h 
before infection or 6h to 10h after infection (Furuta et al., 2005).  
In this work it was demonstrated that treatment of MI-701, oseltamivir and ribavirin in 
combination at 0h to 6h p.i. was necessary to efficiently suppress the later rounds of 
virus replication (Fig. 4.16). 
5.5 Development of drug-resistance during drug treatment 
Selection of admantane-resistant mutants occurred in about 30% of treated patients 
(Shiraishi et al., 2003; Harper et al., 2005). These resistant viruses were generated 
rapidly and frequently remain fully fit and transmissible (Herlocher et al., 2002). Since 
2003, the global spread of adamantine-resistant influenza A (H3N2) virus strains and 
isolation of adamantane-resistant pandemic 2009 H1N1 viruses during the 2009 
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influenza pandemic have made this class of drugs basically useless for the treatment 
of influenza infections. Therefore, M2 inhibitors are not recommended for treatment or 
prophylaxis of currently circulating influenza A virus strains (CDC3). Current options for 
influenza treatment are limited to neuraminidase inhibitors. However, cases of 
resistance to oseltamivir were observed in patients infected with the pandemic 2009 
H1N1 virus and during treatment or prophylaxis for HPAIV H5N1 infection. Serial 
passages of human influenza A virus H3N2 in the presence of oseltamivir led to the 
occurrence of three amino acid substitutions, A28T in HA1 and R124M in HA2, R292K 
in NA. The mutations in HA caused a 10-fold decrease in susceptibility to oseltamivir, 
whereas the mutation R292K in NA resulted in a high level of resistance to oseltamivir 
(Tai et al., 1998). Passage of HPAIV H5N1 under the pressure of oseltamivir led to the 
development of a mutation H275Y in NA, and in one strain this mutant was combined 
with the mutation I223M. Both mutations resulted in significantly reduced oseltamivir 
susceptibility (Hurt et al., 2009). Therefore, new strategies, such as combination 
therapy, which can reduce the emergence of drug-resistant viruses, would be 
beneficial (Govorkova & Webster, 2010; Hayden, 2013).  
The work of Ilyushina et al. showed that drug-resistant mutants emerged after five 
sequential passages of human influenza A/Hong Kong/156/97 (H5N1), 
A/Nanchang/1/99 (H1N1), and A/Panama/2007/99 (H3N2) viruses in MDCK cells in 
the presence of either the M2 inhibitor amantadine or neuraminidase inhibitor 
oseltamivir (Ilyushina et al., 2006).  
In the present work HPAIV subtype H7N1 was serially passaged in the presence of 
either oseltamivir or furin inhibitor MI-701 alone in MDCK cells. In parallel, the same 
virus was serially passaged in the presence of both oseltamivir and MI-701. 
Propagation of HPAIV H7N1 virus in the presence of increasing concentration of furin 
inhibitor MI-701 did not induce the development of any mutations in HA or in NA (Fig. 
4.17 and Table 4.2). Viruses that were passaged under the pressure of oseltamivir 
rapidly developed the mutation H275Y in NA (Fig. 4.18 and Table 4.2). And the 
mutation H275Y in NA occurred five passages later in the presence of oseltamivir and 
MI-701 than it occurred in the presence of oseltamivir alone. Besides the mutation 
H275Y, a single mutation N295S and a double mutation I223M/P272H in NA were also 
detected when viruses passaged in the presence of both MI-701 and oseltamivir. 
The H275Y NA mutation is one of the most frequently occurring oseltamivir-resistant 
mutations in influenza A viruses. It is located in the framework region of the NA gene 
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and confers high resistance to oseltamivir (Govorkova, 2013) (Fig. 4.20 and Fig. 5.3). 
Early studies suggested that seasonal influenza A viruses H1N1 and H3N2 with the 
H275Y mutation were less infectious and less transmissible in humans (Carr et al., 
2002; Ives et al., 2002). However, the spread of seasonal influenza A virus 
A/Brisbane/59/2007 with this mutation during the 2007-2009 influenza season in the 
absence of drug pressure indicated that the H275Y mutation may not compromise the 
virus fitness and transmissibility in humans (Baz et al., 2010). It was also described 
that HPAIV subtype H5N1 carrying the H275Y mutation in NA replicated less efficiently 
in the upper respiratory tract of ferrets than the wild type virus H5N1 (Le et al., 2005). 
In this work the dose of oseltamivir required for 50% inhibition of neuraminidase activity 
(IC50) of HPAIV FPV_NAH275Y virus was approximately 780nM, which was 140-fold 
higher compared to that of the wild type virus (Table 4.3). According to the WHO guide 
line, an influenza A virus with > 100-fold reduced IC50 to oseltamivir is highly resistant, 
whereas 10- to 100-fold reduced IC50 indicates reduced susceptibility. Therefore, it 
was demonstrated that HPAIV FPV containing the mutation H275Y confers a high 
resistance to oseltamivir. Replication of this mutant virus in cell cultures was 
comparable to the wild type virus (Fig. 4.22), which so far suggested that acquisition 
of H275Y mutation of HPAIV FPV did not affect the virus fitness. The mechanism for 
undiminished fitness of the H275Y-containing oseltamivir-resistant viruses is not 
completely understood, but it was suggested that the reduced substrate affinity of the 
NA with H275Y mutation may have restored the balance between HA receptor-binding 
and NA receptor-cleaving functionalities that was altered by an earlier NA mutation that 
increased substrate affinity (Hayden & de Jong, 2011).  
The mutation N295S is also located in the framework region of NA (Fig. 5.3). 
Compared to the mutation H275Y it was less resistant to oseltamivir (Kiso et al., 2004; 
Le et al., 2005). Although the development of the mutation N295S in NA was detected 
in very early passage in this work, the N295S-containing FPV variant exhibited mild 
resistance to oseltamivir and reduced virus yield at 18h p.i. and 24h p.i. compared to 
that of the wild type virus.  
The mutation P272H is located neither in the framework region nor in the catalytic 
region in the NA gene and so far it has not been observed in any other influenza virus 
strains (Fig. 4.20). Therefore, it is unclear if the mutation P272H is capable of 
conferring resistance to oseltamivir. The I223 residue is highly conserved across all 
influenza A and B viruses, and forms the hydrophobic pocket of the NA active site 
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together with arginine, serine and glutamic acid at position 224, 246, and 276 (Colman 
et al., 1993). The mutation at the 223 position results in the loss of the hydrophobic 
interaction between the side chain of I223 and oseltamivir (Hurt et al., 2009). So far 
different amino acid substitutions at the residue I223 have been reported. Influenza A 
virus H3N2 with mutation I223V was isolated from an immunocompromised child. The 
single I223V mutation resulted in a mild resistance to oseltamivir, whereas association 
with the primary oseltamivir-resistant mutation E120V led to approximately 300-fold 
reduction of susceptibility to oseltamivir (Baz et al., 2006). The I223R mutation was 
detected alone or along with H275Y in patients infected with the pandemic 2009 H1N1 
virus. The I223R mutation alone resulted in reduced susceptibility to oseltamivir, 
zanamivir and peramivir. Enhanced resistance was also observed for I223R/H275Y 
recombinant viruses (Pizzorno et al., 2012). Another study showed that passaging 
HPAIV H5N1 in the presence of neuraminidase inhibitor induced the development of 
H275Y mutation in the NA gene. One strain carried a H275Y/I223M double mutation, 
which significantly reduced the susceptibility to oseltamivir (Hurt et al., 2009). This work 
showed that FPV with the double mutation I223M/P272H exhibited a mild decrease in 
susceptibility to oseltamivir (Table 4.3), and virus replication was slightly compromised 
in cell cultures compared with the wild type virus (Fig 4.22).  
Although the development of oseltamivir-resistant mutations was not completely 
blocked in the presence of oseltamivir and furin inhibitor, the emergence of higly 
oseltamivir-resistant mutation H275Y was significantly delayed. It should be noted here 
that the initial concentration of oseltamivir influences the velocity of the development 
of oseltamivir-resistant mutations. Viruses passaged in the presence of oseltamivir with 
a higher initial concentration developed resistant mutation H275Y by the third passage, 
whereas viruses passaged with lower initial concentrations of oseltamivir did not 
develop resistant mutations before passage five (data not shown). Therefore, it is of 
great interest to examine the development of resistance in the presence of MI-701 and 
oseltamivir, and the concentration of oseltamivir starts at 0.005µM, which is the 50% 
inhibitory concentration for the virus determined by NA enzyme inhibition assay. 
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Fig. 5.3: Crystal structure of NA monomer. (A) NA monomer excised from an NA-tetramer is shown 
in surface representation. (B) Detailed view of NA catalytic domain is presented. Several amino acids 
are labelled with the number of their amino acid positions. Amino acid substitutions at these positions 
have been reported to confer susceptibility to neuraminidase inhibitors (N1 numbering) (Lackenby et al., 
2008). The amino acids in the catalytic site of NA are indicated in yellow and amino acids belonging to 
the framework residues are shown in blue. The crystal structure is available from the RCSB PDB under 
accession codes 2HTY for the avian influenza H5N1.  
 
Moreover, replication of FPV wild type or FPV mutants in MDCK cells in the presence 
of furin inhibitor MI-701 was suppressed in the same way, suggesting that furin 
inhibitors should be an alternative antiviral drug for treatment of oseltamivir-resistant 
HPAIV infection (Fig. 4.23).  
5.6 Furin inhibitors block other viruses and bacterial pathogens 
Currently, most prophylactic and therapeutic approaches are virus specific. 
Development of inhibitors with a broad substrates spectrum would be beneficial for the 
treatment of a wide range of severe diseases. 
Furin is involved in processing the precursors of many other infectious pathogens (See 
1.3.1). Besides the HA protein of HPAIV, furin is responsible for the activation of many 
precursors from different virus families, such as the glycoprotein of Ebola virus (EBOV) 
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and Marburg virus (MARV), which belongs to the family Filoviridae (Volchkov et al., 
1998, 2000), the membrane protein of Dengue virus (DENV) (Keelapang et al., 2004) 
from the family Flaviviridae, the fusion protein of Newcastle disease virus (NDV) (Fujii 
et al., 1999) and respiratory syncytial virus (RSV) (Zimmer et al., 2001) from the family 
Paramyxoviridae, and glycoprotein of human immunodeficiency virus (HIV) from the 
family Retroviridae (Hallenberger et al., 1992). Furin is also responsible for the 
activation of various bacterial toxins, including the Shiga toxin (Garred et al., 1995) and 
Diphtheria toxin (Tsuneoka et al., 1993), the protective antigen of the Anthrax toxin 
(Klimpel et al., 1992), Clostridium α-toxin (Gordon et al., 1997) and Pseudomonas 
extoxin A (Chiron et al., 1994) (Table 5.2). 
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Table 5.2: Cleavage motifs in the precursors of different infectious pathogens 
 
[1] Von Messling et al., 2004; [2] Watanabe et al., 1995; [3] Fujii et al., 1999; [4] Ortmann et al., 1994; 
[5] Bolt et al., 2000; [6] Zimmer et al., 2001; [7] Volchkov et al., 1998; [8] Volchkov et al., 2000; [9] Ozden 
et al., 2008; [10] Follis et al., 2006 [11] Keelapang et al., 2004; [12] Konishi et al., 2001; [13] Stadler et 
al., 1997; [14] Hallenberger et al., 1992; [15] Pellett et al., 1985; [16] Vey et al., 1995; [17] Richards et 
al. ,2006; [18] Klimpel et al., 1992; [19] Gordon et al., 1997; [20] Chiron et al., 1994; [21] Garred et al., 
1995. 
 
In 1992 Hallenberger et al. showed that furin inhibitor dec-RVKR-cmk was able to 
inhibit the cleavage of HIV glycoprotein gp160 and reduced the yields of infectious 
virions (Hallenberger et al., 1992). The engineered furin inhibitor α1-PDX inhibited the 
activation of fusion protein of measles virus (MV) and the glycoprotein gB of human 
cytomegalovirus (HCMV) and thus led to a strong reduction of the virus titer (Watanabe 
et al., 1995, Jean et al., 1999). The work of Ozden et al. showed that furin inhibitor 
dec-RVKR-cmk inhibited the cleavage of the Chikungunya virus (CHIKV) glycoprotein 
E3E2 and significantly suppressed the virus infection in human muscle satellite cells 
(Ozden et al., 2008). The therapeutic effect of furin inhibitor dec-RVKR-cmk and hexa-
D-arginine (D6R) for treatment of the chronic hepatitis B virus (HBV) infection was 
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studied by Pang and co-workers. Treatment with dec-RVKR-cmk directly inhibited 
HBeAg (Hepatitis B e antigen) secretion and thereby increased the expression of 
HBeAg precursor on the cell surface. This may terminate the host immune tolerance, 
and therefore it would be favourable for the early intervention in chronic HBV infection 
(Pang et al., 2013). In addition to the therapeutic effects against virus infections, furin 
inhibitors are also used for the treatment of bacterial infections. The work of Sarac et 
al. showed that furin inhibitor D6R blocked the activation of Pseudomonas exotoxin A 
(PEA) protein (Sarac et al., 2002).  
The therapeutic effects of furin inhibitor MI-701 against different infectious pathogens 
were evaluated. The work of Becker et al. showed that furin inhibitor MI-701 potently 
inhibited the proteolytic activation of HPAIV HA and virus replication in cells cultures 
and the activation of Shiga toxin in HEp-2 cells (Becker et al., 2012). The syncytial 
formation in BHK-21 cells induced by the NDV strain Italien and RSV strain A2 was 
significantly suppressed in the presence of MI-701 from 10µM to 50µM, and release of 
NDV strain Italien was completely blocked during the course of experimentation (96h) 
in the presence of 50µM MI-701 (data not shown).  
5.7 Conclusion 
This thesis demonstrated the potent inhibitory efficacy of peptidomimetic furin inhibitors 
against HPAIV infections and the benefits of combinatorial drug treatments, which 
surpassed single drug treatments in cell cultures. Moreover, a significant suppression 
of emergency of oseltamivir resistant NA-variants was observed during double 
treatment with oseltamivir and furin inhibitor. These data provide a basis for further 
studying therapeutic efficacy of furin inhibitors in animal experiments before starting 
clinical trials. 
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6. Supplementary data 
Table S1: Outbreak of HPAIV H7 subtypes in poultry since 1959. 
 
*Table is taken from Alexander et al., 2007 and Harder & Werner, 2006 with modifications. 
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Table S2: Outbreaks of HPAIV H5 subtypes in poultry since 1959.  
 
*Table is taken from Alexander et al., 2007 and Harder & Werner, 2006 with modification. 
 
 
Fig. S1: Structures of oseltamivir and ribavirin. 
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Table S3: Structures of P5-modified furin inhibitors. 
 
 
 
Inhibitor P5 Sequence 
Ki 
(nM) 
IC50 
(nM) 
MI-227 
O  
Phenylacetyl-Arg-Val-Arg-4-Amba 0.81 nd 
MI-230 
O  
Acetyl-Arg-Val-Arg-4-Amba 1.0 nd 
MI-255 
O  
Butanoyl-Arg-Val-Arg-4-Amba 0.67 nd 
MI-256 
O
3
 
Hexanoyl-Arg-Val-Arg-4-Amba 0.78 nd 
MI-257 
O
5
 
Octanoyl-Arg-Val-Arg-4-Amba 0.67 2.3 
MI-231 
O
7
 
Decanoyl-Arg-Val-Arg-4-Amba 1.6 8.3 
MI-258 
O
9
 
Dodecanoyl-Arg-Val-Arg-4-Amba 5.6 nd 
MI-259 
O
11
 
Tetradecanoyl-Arg-Val-Arg-4-Amba 50 396 
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MI-232 
O
13
 
Palmitoyl-Arg-Val-Arg-4-Amba nd 80 
MI-233 
O
15
 
Stearyl-Arg-Val-Arg-4-Amba nd 14010 
MI-283 O
67
 
Olenoyl-Arg-Val-Arg-4-Amba nd 272 
MI-284 O
64
 
Linoyl-Arg-Val-Arg-4-Amba 5.3 22 
MI-299 
O
3
H
NH2N
NH  
Guanidino-valerinoyl-Arg-Val-Arg-
4-Amba 
0.062 nd 
MI-701 
OHN
NHH2N
 
4-guanidinomethyl-phenylacetyl-
Arg-Val-Arg-4-Amba 
0.016 nd 
MI-0052 
O
N
H
NH
H2N
 
3-guanidinomethyl-phenylacetyl-
Arg-Val-Arg-4-Amba 
0.008 nd 
 
Ki values are determined under tight-binding conditions. Table is taken from Becker et al., 2012 with 
modification.  
Amba= 4-amidinobenzylamide; nd = not determined. 
 
 
 
 
 
 
 
6. Supplementary  
110 
 
Fig. S2: Inhibition proteolytic activation of HPAIV H5N1 subtype virus by furin 
inhibitor MI-701. 
 
 
 
MDCK cells were infected with KAN-1 at an MOI of 10. After virus adsorption, infected cells were treated 
with MI-701 at concentrations of 0.1µM, 1µM, 10µM, 25µM and 50µM, respectively or without inhibitor 
treatment. At 24h p.i. cell lysates were collected and subjected to SDS-PAGE and Western blot. Viral 
protein bands were visualized using antiserum against FPV and anti-tubulin antibody as loading control. 
For quantification, each HA0 band was standardized correlating to the β-tubulin bands (A) and the 
amount of HA0 obtained in cells treated with 50µM MI-701 or without treatment were normalized to 100% 
and 0%, respectively. The intensities of protein bands were measured by the program Odyssey 2.01.  
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Fig. S3: Microscopy images of virus spread in the presence of MI-701 and 
oseltamivir alone or in combination. 
 
 
 
MDCK cells were infected with FPV at an MOI of 0.001. Infected cells were treated with inhibitor MI-701 
at a concentration of 10µM, 25µM or 50µM and oseltamivir at a concentration of 0.01µM, 0.1µM or 
0.5µM alone or in combination. As controls, both uninfected cells (mock) and infected cells were 
incubated in pure medium in the absence of inhibitor. At 24h p.i. cells were fixed with 4% PFA and 
infected cells were immunostained using anti-FPV antibody and HRP-conjugated anti-rabbit secondary 
antibody.  
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Fig. S4: Reduction of EC50 for MI-701 as single agent or in double and triple 
combinations. 
 
 
 
EC50 calculations were made by normalizing the NR data for each well against the uninfected mock 
control data, which was assumed to be 100%. Normalized data were plotted as percent inhibition versus 
compound concentration. The data points were then fitted using four-parameter curve fitting in Graphpad 
Prism (Graphpad Software, La Jolla, CA) to derive the EC50. 
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Table S4: Structures of optimized furin inhibitors. 
 
The cytotoxicity of compounds was determined in MDCK cells by MTT assay (see 3.1.2). 
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Fig. S5: Inhibitory efficacy of newly modified furin inhibitors. 
 
MDCK cells were infected with FPV at an MOI of 0.001. Infected cells were treated with furin inhibitors at the concentration of 1µM, 10µM, 25µM or 50µM or 
incubated without inhibitor treatment. At 24h p.i. cells were fixed with 4% PFA, infected cells were immunostained against anti-FPV antibody and HRP-conjugated 
anti-rabbit secondary antibody (structures are shown in Table S4 in supplementary). 
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Fig. S6: Neutral red data for synergy analysis. 
A     Double combination of MI-701 and oseltamivir  
 
Vertical drug is oseltamivir (µM); Horizontal drug is MI-701 (µM); no third drug; VC = virus control; CC = 
cell control. 
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B   Triple combination of MI-701, oseltamivir and 1µM ribavirin 
 
Vertical drug is oseltamivir (µM); Horizontal drug is MI-701 (µM); the third drug is ribavirin (µM); VC = 
virus control; CC = cell control. 
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C   Triple combination of MI-701, oseltamivir and 10µM ribavirin 
 
Vertical drug is oseltamivir (µM); Horizontal drug is MI-701 (µM); the third drug is ribavirin (µM); VC = 
virus control; CC = cell control. 
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I (Ile)    isoleucine 
K (Lys)    lysine 
L (Leu)    leucine 
M (Met)    methionine 
N (Asn)    asparagine 
P (Pro)    proline 
Q (Gln)    glutamine 
R (Arg)    arginine 
S (Ser)    serine 
T (Thr)    threonine 
W (Trp)    tryptophan 
V (Val)    valine 
Y (Tyr)    tyrosine 
Figures  
135 
 
Figures 
Fig. 1.1: Recorded human influenza pandemics since 1918.             8 
Fig. 1.2: Structure of influenza A virus.             10 
Fig. 1.3: Influenza virus life cycle.             13 
Fig. 1.4: Crystal structure of hemagglutinin (HA).           15 
Fig. 1.5: The role of swine for influenza virus genetic reassortment.         16 
Fig. 1.6: Cleavage of hemagglutinin of influenza A viruses.          17 
Fig. 1.7: Scheme of the furin structure.             20 
Fig. 1.8: Sites of substrates activation by furin.            21 
Fig. 1.9: M2 protein inhibitors.              24 
Fig. 1.10: Neuraminidase inhibitors.             25 
Fig. 1.11: Structure of furin inhibitor MI-701.            28 
Fig. 1.12: Antiviral agents target different steps during influenza virus replication.       30 
Fig. 3.1: Scheme of propagation of FPV in the presence and absence of antivirals in MDCK cells. 
                53 
Fig. 4.1: Cytotoxicity determination of different furin inhibitors in vitro.         58 
Fig. 4.2: Dose-dependent cytotoxicity determination of different inhibitors.        59 
Fig. 4.3: Stability measurement of furin inhibitors.           60 
Fig. 4.4: Cleavage of HA in the presence of different furin inhibitors (A) and quantification  
 of HA cleavage inhibition (B).             61 
Fig. 4.5: Cleavage of HA0 in the presence of inhibitor MI-701 at various concentrations.       63 
Fig. 4.6: Virus spread in the presence of furin inhibitor MI-701.          64 
Fig. 4.7: Inhibition of HPAIV multicycle replication in cell culutures.         65 
Fig. 4.8: Inhibition of the FPV_mutant_HAmono multicycle replication in cell cultures.       66 
Fig. 4.9: Cytotoxicity of MI-701 in double and triple combination with anti-influenza drugs.      68 
Fig. 4.10: Virus spread in the presence of MI-701 and oseltamivir.         69 
Fig. 4.11: HPAIV multicycle replication in the presence of double drugs.         70 
Fig. 4.12A: Multicycle replication of HPAIV subtype H7N1 in the presence of triple drugs.      72 
Fig. 4.12B: Multicycle replication of HPAIV subtype H5N1 in the presence of triple drugs.      73 
Fig. 4.13: Viability of inhibitor treated infected cells at 96h p.i..          74 
Fig. 4.14: Vesicular Stomatitis Virus control infection.           75 
Fig. 4.15: Synergistic inhibition of MI-701 in double combination and triple combination  
   against FPV.               77 
Fig. 4.16: Time of inhibitor addition.             79 
Fig. 4.17: Susceptibility of passaged FPV to furin inhibitor MI-701.         81 
Fig. 4.18: Susceptibility of passaged FPV to oseltamivir.           82 
Fig. 4.19: Sequence analysis is represented in chromatogram.          84 
 
Figures  
136 
 
Fig. 4.20: Crystal structure of group-1 (N1) NA monomer in ribbons representation (A)  
   and NA tetramer in surface representation (B).          85 
Fig. 4.21: NA enzyme inhibition assay of FPV mutants.           86 
Fig. 4.22: Growth FPV wild type and FPV mutants in cell cultures.         88 
Fig. 4.23: Effect of MI-701 on FPV mutants replication.           89 
Fig. 5.1: Binding mode of synthetic inhibitors in the active site of human furin.        95 
Fig. 5.2: Reduction of KAN-1 virus yield at 72h p.i. after inhibitor treatment.        98 
Fig. 5.3: Neuraminidase inhibitor resistant mutations.         102 
Fig. S1: Structures of oseltamivir and ribavirin.          107 
Fig. S2: Inhibition proteolytic activation of HPAIV H5N1 subtype virus by furin inhibitor MI-701.    110 
Fig. S3: Microscopy images of virus spread in the presence of MI-701 and oseltamivir  
alone or in combination.           111 
Fig. S4: Reduction of EC50 for MI-701 as single agent or in double and triple combinations.    112 
Fig. S5: Inhibitory efficacy of newly modified furin inhibitors.        114 
Fig. S6: Neutral red data for synergy analysis.               115-117 
 
Table 1.1: Human cases of influenza A virus H7 subtype infection since 1996.          5 
Table 1.2: Confirmed human H5N1 cases from 2003 to 2014.            7 
Table 1.3: Functions of influenza viral proteins.             11 
Table 4.1: Reduction of EC50 for MI-701 as single agent or in double and triple combinations.      76 
Table 4.2: Sequence analysis of FPV variants in the presence of drugs in vitro.        83 
Table 4.3: Susceptibility of FPV mutants to oseltamivir.           87 
Table 5.1: Reported furin inhibitors.             92 
Table 5.2: Cleavage motifs in the precursors of different infectious pathogens.      104 
Table S1: Outbreak of HPAIV H7 subtypes in poultry since 1959.       106 
Table S2: Outbreaks of HPAIV H5 subtypes in poultry since 1959.        107 
Table S3: Structures of P5-modified furin inhibitors.         108 
Table S4: Structures of optimized furin inhibitors.         115 
 
Curriculum vitae  
137 
 
Curriculum vitae 
Name:   Yinghui Lu 
Birthday:   21st Nov.1983 
Birth place:   Shanghai, China 
Nationality:    chinese  
 
Enducation 
2007-2009    Philipps university Marburg 
    Master programme ‘Molecular and Cellular Biology’ 
              Degree: Master of Science 
2002-2006   Bioscience, Shanghai Normal University  
Degree: Bachelor of Science 
1999-2002   Shangnan high school in Pudong New Distrcit, Shanghai 
1996-1999 The Subsidiary Experimental School of College of 
education in Pudong New Distrcit, Shanghai 
1990-1995  Pusanlu primary school in Pudong New Distrcit, Shanghai 
 
Scholarships 
09/2009-06/2011  PhD student, LOEWE-Stiftung, Hessen  
(Prof. Dr. Wolfgang Garten) 
05/2010-08/2010  Research & Teaching Assistantships (DAAD) 
07/2011-11/2011  Roland und Elfriede-Schauer-Stiftung, PhD scholarship 
12/2011-08/2013  FAZIT-Stiftung, PhD scholarship 
09-2013-12-2014  PhD student, Collaboration research center 593,  
project B1 (Prof. Dr. Hans-Dieter Klenk) 
 
 
 
 
 
 
 
Curriculum vitae  
138 
 
Publications 
Becker GL, Sielaff F, Than ME, Lindberg I, Routhier S, Day R, Lu Y, Garten W & 
Steinmetzer T (2010) Potent inhibitors of furin and furin-like proprotein 
convertases containing decarboxylated P1 arginine mimetics. J. Med. Chem. 53: 
1067–1075. 
Becker GL, Lu Y, Hardes K, Strehlow B, Levesque C, Lindberg I, Sandvig K, Bakowsky 
U, Day R, Garten W & Steinmetzer T (2012) Highly potent inhibitors of proprotein 
convertase furin as potential drugs for treatment of infectious diseases. J. Biol. 
Chem. 287: 21992–22003. 
Böttcher-Friebertshäuser E, Lu Y, Meyer D, Sielaff F, Steinmetzer T, Klenk H-D & 
Garten W (2012) Hemagglutinin activating host cell proteases provide promising 
drug targets for the treatment of influenza A and B virus infections. Vaccine 30: 
7374–7380. 
Paper in preparation 
Lu Y, Hardes K, Böttcher-Friebertshäuser E, Steinmetzer T, Klenk HD, and Garten W 
(2014) Synergistic inhibition of highly pathogenic avian influenza viruses by 
combinatorial treatment with olseltamivir, ribavirin, and a peptidomimetic furin 
inhibitor  
 
Poster presentations 
21th Annual Meeting of the Society for Virology, Freiburg, Germany. (2011)  
“Newly designed peptidomimetics inhibit specific host cell subtilases necessary for 
propagation of distinct viruses.” Lu Y, Fehling SK, Strecker T, Becker G, Steinmetzer 
T and Garten W.  
“Importance of activated viral glycoprotein for spread of Borna disease virus in various 
cell cultures.” Bayer K, Lennartz F, Lu Y, Becker G, Steinmetzer T, Kehr K, Herden C 
and Garten W. 
 
 
 
Curriculum vitae  
139 
 
22th Annual Meeting of the Society for Virology, Essen, Germany. (2012) 
“Synergistic blockage of virus propagation by host cell protease inhibitors combined 
approved drugs.” Fehling SK, Lu Y, Strecker T, Becker G, Steinmetzer T and Garten 
W. 
“Inhibition of IBV infection in Vero cells and chicken tracheal organ cultures by an 
Inhibitor of the cellular protease furin.” Winter C, Lu Y, Herrler G, Steinmetzer T and 
Garten W. 
 
International Symposium of the SFB 593 “Mechanisms of Cellular 
Compartmentalization.” (2012) 
“Synergistic inhibition of virus replication by combination of host cell protease inhibitors 
and approved drugs.” Fehling SK, Lu Y, Strecker T, Becker G, Steinmetzer T and 
Garten W. 
 
3rd International Influenza Meeting, Muenster, Germany. (2012) 
“Newly designed furin-specific inhibitors exhibit potent inhibitory efficacy against highly 
pathogenic influenza viruses.” Lu Y, Becker G, Steinmetzer T and Garten W. 
 
23th Annual Meeting of the Society for Virology, Kiel, Germany. (2013) 
The proteolytic cleavage of the IBV spike protein by furin or other host proteases 
depends on the cell type.” Winter C, Lu Y, Garten W, Steinmetzer T and Herrler G. 
“Propagation of highly pathogenic influenza virus is blocked by combinatorial treatment 
with GS4017, ribavirin and furin inhibitor MI-701.” Lu Y, Becker G, Steinmetzer T and 
Garten W. 
 
Oral presentation 
24th Annual Meeting of the Society for Virology, Alpbach, Austria. (2014) 
“Combinatorial treatment with oseltamivir, ribavirin and furin inhibitor MI-701 inhibits 
propagation of highly pathogenic avian influenza virus and suppresses the 
development of drug-resistant virus mutants.” Lu Y, Becker G, Steinmetzer T, Klenk 
HD and Garten W. 
 
 
Acknowledgement  
140 
 
Acknowledgements 
This research project would not have been possible without support from of many 
people. 
First and foremost, I would like to express my profound gratitude to my advisor, 
Prof. Dr. Wolfgang Garten, who offered guidance and suggestions throughout my PhD 
study. I am also very grateful for his scientific advice, knowledge and many insightful 
discussions and suggestions. 
A special thanks goes to Prof. Dr. Steinmetzer and his team, Dr. Gero Becker and 
Kornelia Hardes, Institute of Pharmaceutical Chemistry, Philipps University Marburg, 
who steadily supplied me with the peptidomimetic inhibitors and gave me lots of 
valuable advice. 
I would like to make a grateful acknowledgement to Prof. Dr. Hans-Dieter Klenk, 
Institute of Virology, Marburg, for his interest in and generous support of my work. I 
also like to thank Dr. Mikhail Matrosovich, Institute of Virology, Marburg, who made the 
influenza virus A/Thailand/1(KAN-1)/2004 (H5N1) from Dr. Puthavathana Mahidol, 
University, Bangkok, Thailand, available for my research.  
I would like to thank Dr. Eva Friebertshäuser for her helpful discussions and advice. 
I am grateful for Emi Takashita, PhD at the Influenza Virus Research Center, National 
Institute of Infectious Disease, Tokyo, Japan, for her useful advices about virus 
inactivation, which made it possible to measure the neuraminidase activity of highly 
pathogenic influenza virus in the BSL 2 lab.  
Many thanks go to Prof. Dr. Mark N. Prichard, Department of Pediatrics, Division of 
Infectious Diseases, University of Alabama at Birmingham, for kindly providing the 
program MacSynergy III for the synergy analysis.  
I am grateful for Dr. Vasundara Srinivasan (LOEWE Center for Synthetic Microbiology-
SYNMIKRO) at the Philipps University Marburg, for kindly showing me how to present 
the 3D model of influenza NA protein using the program Pymol. 
I would also like to acknowledge Vanessa Körner and Cornelia Stoiber for testing 
several furin inhibitors against the infections caused by Newcastle disease virus and 
respiratory syncytial virus in cell cultures.  
I’m thankful for Dr. Volker Czudai-Matwich’s kind help and advice about neuraminidase 
assays.  
Acknowledgement  
141 
 
I am also appreciative of Prof. Dr. Wolfgang Buckel, Prof. Dr. Erhard Bremer and Prof. 
Dr. Susanne Önel, for their friendly support and effort in the thesis committee of the 
Faculty Biology at the Philipps University Marburg.  
I am obliged to all of the people in Institute of Virology, Marburg, especially the present 
and past members of our lab, Dr. Eva Friebertshäuser, Dr. Thomas Strecker, Dr. Sarah 
Katharina Fehling, Dr. Catharina Peitsch, Dr. Frank Lennartz, Dr. Katrin Schlie, Carolin 
Tarnow, Annika Arendt, Petra Neubauer-Rädel, Vanessa Körner and Cornelia Stoiber, 
who gave me assistance and an enjoyable work environment during my study here. 
I’d like to give my special thanks to Leah Demakovsky for her elaborative linguistic 
correction of my thesis. 
I’d like to thank Prof. Dr. Stephan Becker for the opportunity to perform my thesis at 
the Institute of Virology and for his ongoing support. 
I’d like to thank to the Deutsche Forschungsgemeinschaft Sonderforschungsbereich 
593, LOEWE-Stiftung, FAZIT-Stiftung, Roland und Elfriede-Schauer Stifung for 
providing financial aid by turns.  
Last but not least, my utmost gratitude goes to my family. Words fail me to express my 
deepest love for my parents and my sister. Thanks for your understanding and endless 
love. Lastly I’d like to take this opportunity to thank all of my friends for their support. 
 
 
 
 
 
 
 
 
Erklärung  
142 
 
Erklärung 
Ich erkläre, daß ich meine Dissertation 
 
Potent inhibition of highly pathogenic influenza virus infection using a 
peptidomimetic furin inhibitor alone or in combination with conventional 
antiviral agents 
 
selbständig, ohne unerlaubte Hilfe angefertigt und mich dabei keiner anderen als der 
von mir ausdrücklich bezeichneten Quellen und Hilfen bedient habe. Die Dissertation 
wurde in der jetzigen oder einer ähnlichen Form noch keiner anderen Hochschule 
eingereicht und hat noch keinen sonstigen Prüfungszwecken gedient. 
 
 
 
 
Marburg, 14.08.2014    ______________________ 
        Yinghui Lu 
 
